STOCK TITAN

Healthcare Triangle Q3 2026 loss widens to $2.53M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Healthcare Triangle, Inc. (HCTI) reported third-quarter 2026 revenue of $9.116 million, versus $3.489 million a year earlier; customer engagement services contributed $6.525 million following the January 1, 2026 acquisition of Teyame and Datono. Gross margin was $2.081 million, while net loss was $2.532 million, compared with $1.906 million a year earlier.

For the nine months ended September 30, revenue was $28.162 million and net loss was $13.147 million. Operating cash outflow was $10.207 million, and cash and equivalents were $1.869 million on September 30, down from $7.625 million on December 31, 2025. Management said resources were sufficient to meet obligations for at least 12 months from issuance, citing net assets of $50.238 million, an equity line allowing common-stock sales up to $50 million subject to contractual conditions, and access to an at-the-market sales agreement. A one-for-twenty reverse stock split took effect October 26, 2026. An appeal stayed Nasdaq trading suspension and delisting proceedings pending a panel decision; HCTI presented its case on November 5, 2026, and is awaiting the decision.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Moderate pointThird-quarter revenue increased 161% year over year to $9.116 million.

Negative

  • Moderate pointThird-quarter net loss increased to $2.532 million from $1.906 million.
  • Moderate pointCash and equivalents fell to $1.869 million at September 30 from $7.625 million at year-end.

Filing Explained

The proposed Teyame separation would distribute only a portion of its shares to Healthcare Triangle holders, with the company retaining control.

Healthcare Triangle reported a $3,602 thousand fair-value balance for its 2026 convertible notes at September 30, 2026; the notes mature December 12, 2026, and holders may convert them into common shares. After the contractual conversion date, the conversion price is 85% of the common stock’s volume-weighted average price over the preceding three trading days, subject to a floor; conversion would add shares and reduce existing holders’ percentage ownership absent offsetting changes.

By quarter-end, the company had completed two Hudson line draws, leaving approximately $49,662 thousand of contractual commitment; further share sales remain subject to an effective resale registration statement, Nasdaq listing, minimum trading-price requirements and other conditions.

After quarter-end, the company said it was advancing a proposed separation and direct listing of Teyame AI Holdings: it intends to distribute a portion of Teyame’s shares to Healthcare Triangle stockholders while retaining control. The transaction is not complete and remains subject to registration, regulatory and exchange requirements, approvals and other conditions.

Also after quarter-end, the company issued 28,602 common shares through its ATM. Issuing additional shares reduces existing holders’ percentage ownership absent offsetting changes.

Third-quarter revenue $9.116 million Three months ended September 30, 2026; $3.489 million in 2025; reported increase of 161%.
Third-quarter net loss $2.532 million Three months ended September 30, 2026; compared with $1.906 million in 2025.
Customer engagement services revenue $6.525 million Three months ended September 30, 2026.
Nine-month revenue $28.162 million Nine months ended September 30, 2026; $10.752 million in 2025; reported increase of 162%.
Nine-month net loss $13.147 million Nine months ended September 30, 2026; compared with $4.973 million in 2025.
Operating cash used $10.207 million Nine months ended September 30, 2026; compared with $10.156 million in 2025.
Cash and cash equivalents $1.869 million As of September 30, 2026; $7.625 million as of December 31, 2025.
Remaining equity-line commitment Approximately $49.662 million Maximum contractual commitment remaining as of September 30, 2026.
At-the-Market Sales Agreement financial
"pursuant to its At-the-Market Sales Agreement"
An at-the-market sales agreement lets a company raise cash by selling newly issued shares directly into the open market at whatever price buyers are paying that day, using a broker to place the trades over time. Investors should watch these deals because they can dilute existing ownership and put downward pressure on the stock price while giving the company flexible, on-demand funding—like a store gradually listing extra items on an online marketplace at current prices.
Equity Purchase Agreement financial
"entered into an Equity Purchase Agreement"
An equity purchase agreement is a legal contract that sets the terms for buying ownership shares in a company, including the number of shares, price, and any conditions that must be met before the sale closes. For investors it matters because it determines how much ownership and control they gain, how the company’s value and share count change, and what protections or obligations each side has—think of it as the detailed bill of sale and ground rules for a stock purchase.
original issue discount financial
"15% original issue discount senior convertible promissory notes"
Original issue discount (OID) is the difference between a debt security’s face value and the lower price at which it is first sold, treated as additional interest that accrues over the life of the instrument. For investors it matters because OID raises the effective yield and changes taxable income and the holding’s cost basis over time — think of buying a $100 voucher for $90 and recognizing the $10 gain as earned interest as the voucher approaches maturity.
volume-weighted average price financial
"85% of the volume-weighted average price"
Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.
Level 3 financial
"classified within Level 3 of the fair value hierarchy"
Level 3 describes the lowest-confidence category in the accounting “fair value” hierarchy, covering assets or liabilities whose prices are not observable in the market and must be estimated using judgment and internal models. For investors, Level 3 items matter because they can introduce greater uncertainty and potential valuation swings—like valuing a unique antique versus checking a price tag on a supermarket shelf—so they signal higher model risk and lower liquidity.
cost-to-cost method financial
"using the cost-to-cost method"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did HCTI report in Q3 2026?

Healthcare Triangle reported net revenue of $9.116 million for the three months ended September 30, 2026, compared with $3.489 million in the prior-year quarter. Customer engagement services contributed $6.525 million.

How much capacity remained under HCTI’s equity line at September 30, 2026?

About $49.662 million of maximum contractual commitment remained under the Equity Purchase Agreement as of September 30, 2026. HCTI may sell shares at its discretion during a commitment period of up to 36 months, subject to contractual conditions, resale registration, Nasdaq listing and trading-price requirements. Hudson’s purchases are also subject to a 4.99% beneficial ownership limit.

What are the amended purchase terms for HCTI’s Hudson equity line?

The maximum amount per purchase notice was reduced to $250,000, subject to a further limit of 200% of HCTI’s average daily trading value. The purchase price was revised to 94% of the average of the three lowest traded prices during the five trading days before a notice; the minimum trading-price requirement became $0.10 per share before the October 26, 2026 reverse-split adjustment.

What is HCTI’s Nasdaq listing status?

HCTI’s appeal stayed trading suspension and delisting proceedings pending a Nasdaq Hearings Panel decision. The company presented its case on November 5, 2026, and was awaiting the Panel’s decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
P3D P5D 0001839285 false --12-31 Q3 0001839285 2026-07-01 2026-09-30 0001839285 2026-01-01 2026-09-30 0001839285 hcti:NasdaqStockMarketLLCMember 2026-09-30 0001839285 us-gaap:SubsequentEventMember 2026-10-01 0001839285 us-gaap:SubsequentEventMember 2026-10-01 2026-10-01 0001839285 2025-01-01 2025-09-30 0001839285 2025-07-01 2025-09-30 0001839285 2025-01-01 2025-12-31 0001839285 2025-12-31 0001839285 2026-09-30 0001839285 2024-12-31 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerFiveMember us-gaap:SalesRevenueNetMember 2025-01-01 2025-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerFiveMember us-gaap:SalesRevenueNetMember 2025-07-01 2025-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerFourMember us-gaap:SalesRevenueNetMember 2025-01-01 2025-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerFourMember us-gaap:SalesRevenueNetMember 2025-07-01 2025-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerThreeMember us-gaap:SalesRevenueNetMember 2025-01-01 2025-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerThreeMember us-gaap:SalesRevenueNetMember 2025-07-01 2025-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerTwoMember us-gaap:SalesRevenueNetMember 2025-01-01 2025-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerTwoMember us-gaap:SalesRevenueNetMember 2025-07-01 2025-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerOneMember us-gaap:SalesRevenueNetMember 2025-01-01 2025-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerOneMember us-gaap:SalesRevenueNetMember 2025-07-01 2025-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerFiveMember us-gaap:SalesRevenueNetMember 2026-01-01 2026-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerFiveMember us-gaap:SalesRevenueNetMember 2026-07-01 2026-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerFourMember us-gaap:SalesRevenueNetMember 2026-01-01 2026-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerFourMember us-gaap:SalesRevenueNetMember 2026-07-01 2026-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerThreeMember us-gaap:SalesRevenueNetMember 2026-01-01 2026-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerThreeMember us-gaap:SalesRevenueNetMember 2026-07-01 2026-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerTwoMember us-gaap:SalesRevenueNetMember 2026-01-01 2026-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerTwoMember us-gaap:SalesRevenueNetMember 2026-07-01 2026-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerOneMember us-gaap:SalesRevenueNetMember 2026-01-01 2026-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:CustomerOneMember us-gaap:SalesRevenueNetMember 2026-07-01 2026-09-30 0001839285 us-gaap:OperatingSegmentsMember 2025-01-01 2025-09-30 0001839285 hcti:CorporateAndOthersMember 2025-01-01 2025-09-30 0001839285 hcti:TotalReportableSegmentsMember 2025-01-01 2025-09-30 0001839285 hcti:AllOthersMember 2025-01-01 2025-09-30 0001839285 hcti:ManagedServicesAndSupportMember 2025-01-01 2025-09-30 0001839285 hcti:SoftwareServicesMember 2025-01-01 2025-09-30 0001839285 hcti:CorporateAndOtherItemsMember 2025-01-01 2025-09-30 0001839285 us-gaap:OperatingSegmentsMember 2025-07-01 2025-09-30 0001839285 hcti:CorporateAndOtherItemsMember 2025-07-01 2025-09-30 0001839285 hcti:TotalReportableSegmentsMember 2025-07-01 2025-09-30 0001839285 hcti:CorporateAndOthersMember 2025-07-01 2025-09-30 0001839285 hcti:ManagedServicesAndSupportMember 2025-07-01 2025-09-30 0001839285 hcti:SoftwareServicesMember 2025-07-01 2025-09-30 0001839285 us-gaap:OperatingSegmentsMember 2026-01-01 2026-09-30 0001839285 hcti:CorporateAndOtherItemsMember 2026-01-01 2026-09-30 0001839285 hcti:TotalReportableSegmentsMember 2026-01-01 2026-09-30 0001839285 hcti:AllOthersMember 2026-01-01 2026-09-30 0001839285 hcti:CustomerEngagementServicesMember 2026-01-01 2026-09-30 0001839285 hcti:ManagedServicesAndSupportMember 2026-01-01 2026-09-30 0001839285 hcti:SoftwareServicesMember 2026-01-01 2026-09-30 0001839285 us-gaap:OperatingSegmentsMember 2026-07-01 2026-09-30 0001839285 hcti:CorporateAndOtherItemsMember 2026-07-01 2026-09-30 0001839285 hcti:TotalReportableSegmentsMember 2026-07-01 2026-09-30 0001839285 hcti:AllOthersMember 2026-07-01 2026-09-30 0001839285 hcti:CustomerEngagementServicesMember 2026-07-01 2026-09-30 0001839285 hcti:ManagedServicesAndSupportMember 2026-07-01 2026-09-30 0001839285 hcti:SoftwareServicesMember 2026-07-01 2026-09-30 0001839285 hcti:CorporateAndOthersMember 2026-01-01 2026-09-30 0001839285 hcti:CorporateAndOthersMember 2026-07-01 2026-09-30 0001839285 hcti:EquityLineOfCreditMember 2026-09-30 0001839285 hcti:EquityPurchaseAgreementMember 2026-01-01 2026-09-30 0001839285 hcti:EquityPurchaseAgreementMember 2026-09-30 0001839285 us-gaap:CommonStockMember hcti:EquityPurchaseAgreementMember hcti:EquityLineOfCreditMember us-gaap:SubsequentEventMember 2026-10-26 2026-10-26 0001839285 hcti:EquityLineOfCreditMember 2026-01-01 2026-09-30 0001839285 hcti:EquityPurchaseAgreementMember hcti:EquityLineOfCreditMember 2026-09-30 0001839285 us-gaap:SubsequentEventMember 2026-10-26 2026-10-26 0001839285 us-gaap:CommonStockMember hcti:EquityLineOfCreditMember us-gaap:SubsequentEventMember 2026-10-26 2026-10-26 0001839285 hcti:EquityPurchaseAgreementMember hcti:EquityLineOfCreditMember 2026-01-01 2026-09-30 0001839285 srt:MaximumMember 2026-01-01 2026-09-30 0001839285 srt:MinimumMember 2026-01-01 2026-09-30 0001839285 hcti:EquityLineOfCreditMember 2026-06-12 2026-06-12 0001839285 hcti:AttheMarketSalesAgreementMember 2026-01-01 2026-09-30 0001839285 hcti:PrefundedWarrantsMember 2026-01-01 2026-09-30 0001839285 hcti:EquityFinancingMember 2026-09-30 0001839285 hcti:AttheMarketSalesAgreementMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-10-26 2026-10-26 0001839285 us-gaap:SubsequentEventMember hcti:At-The-MarketPlacementsMember 2026-10-26 2026-10-26 0001839285 hcti:EquityFinancingMember 2026-01-01 2026-09-30 0001839285 hcti:EquityFinancingMember us-gaap:CommonStockMember hcti:PrefundedWarrantsMember 2026-01-01 2026-09-30 0001839285 us-gaap:CommonStockMember hcti:PrefundedWarrantsMember us-gaap:SubsequentEventMember 2026-10-26 2026-10-26 0001839285 hcti:PrefundedWarrantsMember 2026-09-30 0001839285 us-gaap:SubsequentEventMember us-gaap:WarrantMember 2026-10-26 2026-10-26 0001839285 hcti:PrefundedWarrantsMember 2026-02-26 2026-02-26 0001839285 hcti:EquityFinancingMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-10-26 2026-10-26 0001839285 hcti:SecuritiesPurchaseAgreementsMember hcti:PrefundedWarrantsMember 2026-02-26 2026-02-26 0001839285 hcti:EquityFinancingMember us-gaap:CommonStockMember 2026-02-26 2026-02-26 0001839285 2026-02-26 2026-02-26 0001839285 us-gaap:CommonStockMember hcti:TwoThousandTwentyFiveDebenturesMember us-gaap:SubsequentEventMember 2026-10-26 2026-10-26 0001839285 hcti:TwoThousandTwentyFiveDebenturesMember 2026-01-01 2026-09-30 0001839285 us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0001839285 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001839285 hcti:PreferredSeriesBStockMember hcti:SecureKloudTechnologiesLtd.Member 2026-09-30 0001839285 hcti:PreferredSeriesBStockMember 2026-09-30 0001839285 hcti:PreferredSeriesBStockMember 2026-07-22 0001839285 us-gaap:PreferredStockMember us-gaap:SubsequentEventMember hcti:PreferredSeriesBStockMember 2026-10-26 2026-10-26 0001839285 hcti:PreferredSeriesBStockMember 2026-06-24 2026-06-24 0001839285 hcti:PreferredSeriesBStockMember 2026-07-28 0001839285 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001839285 us-gaap:WarrantMember 2025-09-30 0001839285 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001839285 us-gaap:WarrantMember 2024-12-31 0001839285 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001839285 us-gaap:WarrantMember 2026-09-30 0001839285 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001839285 us-gaap:WarrantMember 2025-12-31 0001839285 hcti:EquityLineOfCreditMember us-gaap:SubsequentEventMember us-gaap:WarrantMember 2026-10-26 2026-10-26 0001839285 hcti:PrefundedWarrantsMember hcti:EquityPurchaseAgreementMember 2026-06-12 0001839285 hcti:PrefundedWarrantsMember hcti:EquityPurchaseAgreementMember 2026-06-12 2026-06-12 0001839285 us-gaap:CommonStockMember hcti:PrefundedWarrantsMember 2026-01-01 2026-09-30 0001839285 hcti:HealthcareTriangleIncMember us-gaap:CommonStockMember hcti:PrefundedWarrantsMember 2026-01-01 2026-09-30 0001839285 2026-02-26 0001839285 hcti:PrefundedWarrantsMember us-gaap:SubsequentEventMember 2026-10-26 2026-10-26 0001839285 us-gaap:CommonStockMember 2026-02-26 2026-02-26 0001839285 2026-10-26 2026-10-26 0001839285 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-10-26 2026-10-26 0001839285 hcti:SecuritiesPurchaseAgreementsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-10-26 2026-10-26 0001839285 us-gaap:PreferredStockMember 2026-09-30 0001839285 us-gaap:CommonStockMember 2026-01-22 0001839285 2026-01-22 2026-01-22 0001839285 hcti:HealthcareTriangleIncMember 2026-01-22 2026-01-22 0001839285 hcti:TeyameAndDatonoMember 2026-01-22 0001839285 hcti:TeyameAndDatonoMember 2026-01-22 2026-01-22 0001839285 hcti:DeutscheFourMember 2026-09-30 0001839285 hcti:DeutscheFourMember 2026-01-01 2026-09-30 0001839285 hcti:DeutscheFourMember 2025-12-31 0001839285 hcti:CaixabankFiveMember 2026-09-30 0001839285 hcti:CaixabankFiveMember 2026-01-01 2026-09-30 0001839285 hcti:CaixabankFiveMember 2025-12-31 0001839285 hcti:DeutscheThreeMember 2026-09-30 0001839285 hcti:DeutscheThreeMember 2026-01-01 2026-09-30 0001839285 hcti:DeutscheThreeMember 2025-12-31 0001839285 hcti:BBVAThreeMember 2026-01-01 2026-09-30 0001839285 hcti:BBVAThreeMember 2025-12-31 0001839285 hcti:DeutscheTwoMember 2026-09-30 0001839285 hcti:DeutscheTwoMember 2026-01-01 2026-09-30 0001839285 hcti:IbercajaMember 2026-09-30 0001839285 hcti:IbercajaMember 2026-01-01 2026-09-30 0001839285 hcti:IbercajaMember 2025-12-31 0001839285 hcti:CaixabankFourMember 2026-09-30 0001839285 hcti:CaixabankFourMember 2026-01-01 2026-09-30 0001839285 hcti:CaixabankFourMember 2025-12-31 0001839285 hcti:BBVAClickPayOneMember 2026-09-30 0001839285 hcti:BBVAClickPayOneMember 2026-01-01 2026-09-30 0001839285 hcti:BBVAClickPayOneMember 2025-12-31 0001839285 hcti:BBVATwoMember 2026-09-30 0001839285 hcti:BBVATwoMember 2026-01-01 2026-09-30 0001839285 hcti:BBVATwoMember 2025-12-31 0001839285 hcti:BsantanderOneMember 2026-01-01 2026-09-30 0001839285 hcti:BankinterLneaPagoImpuestosOneMember 2026-01-01 2026-09-30 0001839285 hcti:BankinterLneaPagoImpuestosOneMember 2025-12-31 0001839285 hcti:BankinterTwoMember 2026-01-01 2026-09-30 0001839285 hcti:CaixabankThreeMember 2026-09-30 0001839285 hcti:CaixabankThreeMember 2026-01-01 2026-09-30 0001839285 hcti:AbancaOneMember 2026-09-30 0001839285 hcti:AbancaOneMember 2026-01-01 2026-09-30 0001839285 hcti:AbancaOneMember 2025-12-31 0001839285 hcti:IbercajaMultiproductoMultiempresaOneMember 2026-09-30 0001839285 hcti:IbercajaMultiproductoMultiempresaOneMember 2026-01-01 2026-09-30 0001839285 hcti:IbercajaMultiproductoMultiempresaOneMember 2025-12-31 0001839285 hcti:DeutscheOneMember 2026-09-30 0001839285 hcti:DeutscheOneMember 2026-01-01 2026-09-30 0001839285 hcti:DeutscheOneMember 2025-12-31 0001839285 hcti:CaixabankTwoMember 2026-09-30 0001839285 hcti:CaixabankTwoMember 2026-01-01 2026-09-30 0001839285 hcti:CaixabankTwoMember 2025-12-31 0001839285 hcti:BankinterOneMember 2026-09-30 0001839285 hcti:BankinterOneMember 2026-01-01 2026-09-30 0001839285 hcti:BankinterOneMember 2025-12-31 0001839285 hcti:BBVAOneMember 2026-09-30 0001839285 hcti:BBVAOneMember 2026-01-01 2026-09-30 0001839285 hcti:BBVAOneMember 2025-12-31 0001839285 hcti:BsabadellMember 2026-09-30 0001839285 hcti:BsabadellMember 2026-01-01 2026-09-30 0001839285 hcti:BsabadellMember 2025-12-31 0001839285 hcti:BankiaMember 2026-01-01 2026-09-30 0001839285 hcti:BankiaMember 2025-12-31 0001839285 hcti:DeutscheMember 2026-09-30 0001839285 hcti:DeutscheMember 2026-01-01 2026-09-30 0001839285 hcti:TargobankMember 2026-01-01 2026-09-30 0001839285 hcti:TargobankMember 2025-12-31 0001839285 hcti:IbercajaMultiproductoMultiempresaMember 2026-09-30 0001839285 hcti:IbercajaMultiproductoMultiempresaMember 2026-01-01 2026-09-30 0001839285 hcti:IbercajaMultiproductoMultiempresaMember 2025-12-31 0001839285 hcti:UnicajaMember 2026-09-30 0001839285 hcti:UnicajaMember 2026-01-01 2026-09-30 0001839285 hcti:UnicajaMember 2025-12-31 0001839285 hcti:AbancaMember 2026-09-30 0001839285 hcti:AbancaMember 2026-01-01 2026-09-30 0001839285 hcti:AbancaMember 2025-12-31 0001839285 hcti:CaixabankOneMember 2026-09-30 0001839285 hcti:CaixabankOneMember 2026-01-01 2026-09-30 0001839285 hcti:CaixabankOneMember 2025-12-31 0001839285 hcti:BBVAClickPayMember 2026-09-30 0001839285 hcti:BBVAClickPayMember 2026-01-01 2026-09-30 0001839285 hcti:BBVAClickPayMember 2025-12-31 0001839285 hcti:BBVAMember 2026-09-30 0001839285 hcti:BBVAMember 2026-01-01 2026-09-30 0001839285 hcti:BBVAMember 2025-12-31 0001839285 hcti:BsantanderMember 2026-01-01 2026-09-30 0001839285 hcti:BankinterLneaPagoImpuestosMember 2026-01-01 2026-09-30 0001839285 hcti:BankinterMember 2026-01-01 2026-09-30 0001839285 hcti:CaixabankMember 2026-09-30 0001839285 hcti:CaixabankMember 2026-01-01 2026-09-30 0001839285 hcti:CaixabankMember 2025-12-31 0001839285 hcti:IbercajaMultipruductoMember 2026-01-01 2026-09-30 0001839285 hcti:IbercajaMultipruductoMember 2025-12-31 0001839285 srt:MaximumMember hcti:TeyameAndDatonoMember 2026-09-30 0001839285 srt:MinimumMember hcti:TeyameAndDatonoMember 2026-09-30 0001839285 hcti:TeyameAndDatonoMember 2026-09-30 0001839285 hcti:TeyameAndDatonoMember 2026-01-01 2026-09-30 0001839285 2026-10-01 2026-10-01 0001839285 hcti:TwoThousandTwentyFiveDebentures1Member 2026-09-30 0001839285 hcti:TwoThousandTwentyFiveDebentures1Member 2026-01-01 2026-09-30 0001839285 hcti:TwoZeroTwoSixConvertibleNotesMember 2026-01-01 2026-09-30 0001839285 hcti:TwoZeroTwoSixConvertibleNotesMember 2026-09-30 0001839285 hcti:TwoZeroTwoSixConvertibleNotesMember 2026-06-12 0001839285 hcti:TwoZeroTwoSixConvertibleNotesMember 2026-06-12 2026-06-12 0001839285 2026-06-12 0001839285 2026-06-12 2026-06-12 0001839285 hcti:TwoThousandTwentySixDebenturesMember 2025-12-31 0001839285 hcti:TwoThousandTwentySixDebenturesMember 2025-01-01 2025-12-31 0001839285 hcti:TwoThousandTwentySixDebenturesMember 2026-01-01 2026-09-30 0001839285 hcti:TwoThousandTwentySixDebenturesMember 2024-12-31 0001839285 srt:MaximumMember 2026-09-30 0001839285 srt:MinimumMember 2026-09-30 0001839285 hcti:SBFFacilityMember 2025-12-31 0001839285 hcti:SBFFacilityMember 2026-09-30 0001839285 hcti:SBFFacilityMember 2025-01-01 2025-12-31 0001839285 hcti:SBFFacilityMember 2026-01-01 2026-09-30 0001839285 hcti:OthersMember 2025-12-31 0001839285 hcti:OthersMember 2026-09-30 0001839285 hcti:DebtWithCreditInstitutionsMember 2026-09-30 0001839285 hcti:ConvertibleNotesMember 2025-12-31 0001839285 hcti:ConvertibleNotesMember 2026-09-30 0001839285 hcti:RecourseFinancingMember 2025-12-31 0001839285 hcti:RecourseFinancingMember 2026-09-30 0001839285 hcti:ParkingSpaceMember 2026-09-30 0001839285 us-gaap:VehiclesMember 2026-09-30 0001839285 us-gaap:BuildingMember 2026-09-30 0001839285 hcti:RightofUseAssetsMember 2026-01-01 2026-09-30 0001839285 us-gaap:FurnitureAndFixturesMember 2026-01-01 2026-09-30 0001839285 us-gaap:FurnitureAndFixturesMember 2025-12-31 0001839285 us-gaap:FurnitureAndFixturesMember 2025-01-01 2025-12-31 0001839285 us-gaap:FurnitureAndFixturesMember 2026-09-30 0001839285 hcti:SoftwareMember 2025-12-31 0001839285 hcti:SoftwareMember 2025-01-01 2025-12-31 0001839285 hcti:SoftwareMember 2026-09-30 0001839285 us-gaap:TrademarksMember 2025-12-31 0001839285 us-gaap:TrademarksMember 2025-01-01 2025-12-31 0001839285 us-gaap:TrademarksMember 2026-09-30 0001839285 us-gaap:TrademarksMember 2026-01-01 2026-09-30 0001839285 us-gaap:IntellectualPropertyMember 2025-12-31 0001839285 us-gaap:IntellectualPropertyMember 2025-01-01 2025-12-31 0001839285 us-gaap:IntellectualPropertyMember 2026-09-30 0001839285 us-gaap:IntellectualPropertyMember 2026-01-01 2026-09-30 0001839285 hcti:SharePurchaseAgreementMember 2026-01-01 2026-01-01 0001839285 hcti:SharePurchaseAgreementMember 2026-01-01 0001839285 2026-01-01 0001839285 us-gaap:CommonStockMember hcti:Pre-FundedWarrantsMember 2026-01-01 2026-09-30 0001839285 us-gaap:CommonStockMember us-gaap:SubsequentEventMember hcti:Pre-FundedWarrantsMember 2026-10-26 2026-10-26 0001839285 hcti:Pre-FundedWarrantsMember 2026-01-01 2026-09-30 0001839285 us-gaap:CommonStockMember hcti:Pre-FundedWarrantsMember 2026-09-30 0001839285 hcti:AdvanceAgreementMember 2026-04-29 2026-04-29 0001839285 hcti:AdvanceAgreementMember 2026-09-01 2026-09-30 0001839285 hcti:AdvanceAgreementMember 2026-04-01 2026-04-30 0001839285 hcti:AdvanceAgreementMember 2026-01-01 2026-01-31 0001839285 hcti:AdvanceAgreementMember 2025-12-31 2025-12-31 0001839285 hcti:EzovionSolutionsPrivateLimitedMember 2026-09-30 0001839285 us-gaap:SeriesBPreferredStockMember 2026-07-01 2026-09-30 0001839285 hcti:RobinsonVincentMember us-gaap:SubsequentEventMember 2026-10-26 2026-10-26 0001839285 hcti:RobinsonVincentMember 2026-09-30 0001839285 hcti:SecureKloudTechnologiesLtd.Member us-gaap:SubsequentEventMember 2026-10-26 2026-10-26 0001839285 hcti:SecureKloudTechnologiesLtd.Member 2026-09-30 0001839285 hcti:AmountsAdvancedMember hcti:BoardOfDirectorsMember 2026-01-01 2026-09-30 0001839285 hcti:AmountsAdvancedMember hcti:BoardOfDirectorsMember 2026-07-01 2026-09-30 0001839285 hcti:CompensationMember hcti:BoardOfDirectorsMember 2026-01-01 2026-09-30 0001839285 hcti:CompensationMember hcti:BoardOfDirectorsMember 2026-07-01 2026-09-30 0001839285 hcti:RemunerationMember hcti:KeyManagementPersonnelMember 2025-01-01 2025-09-30 0001839285 hcti:RemunerationMember hcti:KeyManagementPersonnelMember 2026-01-01 2026-09-30 0001839285 hcti:RemunerationMember hcti:KeyManagementPersonnelMember 2025-07-01 2025-09-30 0001839285 hcti:RemunerationMember hcti:KeyManagementPersonnelMember 2026-07-01 2026-09-30 0001839285 hcti:BlockedgeTechnologiesIncMember hcti:RevenueMember 2025-01-01 2025-09-30 0001839285 hcti:BlockedgeTechnologiesIncMember hcti:RevenueMember 2025-07-01 2025-09-30 0001839285 hcti:AmountsAdvancedMember hcti:BlockedgeTechnologiesIncMember 2025-01-01 2025-09-30 0001839285 hcti:AmountsAdvancedMember hcti:BlockedgeTechnologiesIncMember 2025-07-01 2025-09-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:BlockedgeTechnologiesIncMember 2025-01-01 2025-09-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:BlockedgeTechnologiesIncMember 2026-01-01 2026-09-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:BlockedgeTechnologiesIncMember 2025-07-01 2025-09-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:BlockedgeTechnologiesIncMember 2026-07-01 2026-09-30 0001839285 hcti:RentExpensesPaidMember hcti:SecureKloudTechnologiesIncMember 2025-01-01 2025-09-30 0001839285 hcti:RentExpensesPaidMember hcti:SecureKloudTechnologiesIncMember 2025-07-01 2025-09-30 0001839285 hcti:AmountsCollectedByRelatedPartyOnBehalfOfTheCompanyMember hcti:SecureKloudTechnologiesIncMember 2025-01-01 2025-09-30 0001839285 hcti:AmountsCollectedByRelatedPartyOnBehalfOfTheCompanyMember hcti:SecureKloudTechnologiesIncMember 2025-07-01 2025-09-30 0001839285 hcti:SecureKloudTechnologiesIncMember hcti:ServicesRenderedMember 2025-01-01 2025-09-30 0001839285 hcti:AmountsAdvancedMember hcti:SecureKloudTechnologiesIncMember 2025-01-01 2025-09-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:SecureKloudTechnologiesIncMember 2025-01-01 2025-09-30 0001839285 hcti:AmountsAdvancedMember hcti:SecureKloudTechnologiesIncMember 2026-01-01 2026-09-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:HealthcareTrianglePvtLimitedIndiaMember 2026-01-01 2026-09-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:HealthcareTrianglePvtLimitedIndiaMember 2026-07-01 2026-09-30 0001839285 hcti:AmountsAdvancedMember hcti:SecureKloudTechnologiesLimitedIndiaMember 2025-01-01 2025-09-30 0001839285 hcti:AmountsAdvancedMember hcti:SecureKloudTechnologiesLimitedIndiaMember 2026-01-01 2026-09-30 0001839285 hcti:AmountsAdvancedMember hcti:SecureKloudTechnologiesLimitedIndiaMember 2025-07-01 2025-09-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:SecureKloudTechnologiesLimitedIndiaMember 2025-01-01 2025-09-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:SecureKloudTechnologiesLimitedIndiaMember 2026-01-01 2026-09-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:SecureKloudTechnologiesLimitedIndiaMember 2025-07-01 2025-09-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:SecureKloudTechnologiesLimitedIndiaMember 2026-07-01 2026-09-30 0001839285 hcti:SecureKloudTechnologiesLtd.Member 2026-01-01 2026-09-30 0001839285 hcti:ContractorForServicesMember 2025-12-31 0001839285 hcti:ContractorForServicesMember 2026-09-30 0001839285 hcti:AIToolsAndSoftwareDevelopmentMember 2025-12-31 0001839285 hcti:AIToolsAndSoftwareDevelopmentMember 2026-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:FiveCustomersMember us-gaap:AccountsReceivableMember 2025-12-31 2025-12-31 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:FiveCustomersMember us-gaap:AccountsReceivableMember 2026-09-30 2026-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:FiveCustomersMember us-gaap:SalesRevenueNetMember 2025-07-01 2025-09-30 0001839285 us-gaap:CustomerConcentrationRiskMember hcti:FiveCustomersMember us-gaap:SalesRevenueNetMember 2026-07-01 2026-09-30 0001839285 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001839285 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001839285 us-gaap:FairValueInputsLevel3Member 2026-09-30 0001839285 us-gaap:FairValueInputsLevel1Member 2026-09-30 0001839285 hcti:QuantumNexisIncMember 2026-01-01 2026-09-30 0001839285 hcti:QuantumNexisIncMember 2026-09-30 0001839285 2025-09-30 0001839285 us-gaap:RetainedEarningsMember 2025-09-30 0001839285 us-gaap:NoncontrollingInterestMember 2025-09-30 0001839285 hcti:CommonStockToBeIssuedMember 2025-09-30 0001839285 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001839285 us-gaap:CommonStockMember 2025-09-30 0001839285 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0001839285 hcti:CommonStockToBeIssuedMember 2025-01-01 2025-09-30 0001839285 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001839285 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001839285 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-09-30 0001839285 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-09-30 0001839285 us-gaap:RetainedEarningsMember 2024-12-31 0001839285 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001839285 us-gaap:CommonStockMember 2024-12-31 0001839285 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001839285 hcti:CommonStockToBeIssuedMember 2025-07-01 2025-09-30 0001839285 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001839285 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001839285 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001839285 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-09-30 0001839285 2025-06-30 0001839285 us-gaap:RetainedEarningsMember 2025-06-30 0001839285 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001839285 us-gaap:CommonStockMember 2025-06-30 0001839285 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0001839285 us-gaap:RetainedEarningsMember 2026-09-30 0001839285 us-gaap:NoncontrollingInterestMember 2026-09-30 0001839285 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001839285 us-gaap:CommonStockMember 2026-09-30 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0001839285 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001839285 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001839285 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0001839285 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-09-30 0001839285 us-gaap:RetainedEarningsMember 2025-12-31 0001839285 us-gaap:NoncontrollingInterestMember 2025-12-31 0001839285 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001839285 us-gaap:CommonStockMember 2025-12-31 0001839285 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001839285 2026-09-01 2026-09-30 0001839285 us-gaap:CommonStockMember 2026-09-01 2026-09-30 0001839285 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001839285 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001839285 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001839285 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001839285 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001839285 us-gaap:NoncontrollingInterestMember 2026-07-01 2026-09-30 0001839285 2026-06-30 0001839285 us-gaap:RetainedEarningsMember 2026-06-30 0001839285 us-gaap:NoncontrollingInterestMember 2026-06-30 0001839285 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001839285 us-gaap:CommonStockMember 2026-06-30 0001839285 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001839285 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001839285 us-gaap:SeriesBPreferredStockMember 2025-12-31 0001839285 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001839285 us-gaap:SeriesAPreferredStockMember 2026-09-30 0001839285 2026-11-11 0001839285 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0001839285 hcti:RentExpensesPaidMember hcti:SecureKloudTechnologiesIncMember 2026-01-01 2026-09-30 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-09-30 0001839285 hcti:IbercajaMultipruductoMember 2026-09-30 0001839285 hcti:BankinterLneaPagoImpuestosOneMember 2026-09-30 0001839285 hcti:DebtWithCreditInstitutionsMember 2025-12-31 0001839285 hcti:SoftwareMember 2026-01-01 2026-09-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:HealthcareTrianglePvtLimitedIndiaMember 2025-07-01 2025-09-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:SecureKloudTechnologiesIncMember 2026-07-01 2026-09-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:SecureKloudTechnologiesIncMember 2026-01-01 2026-09-30 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0001839285 hcti:BankinterLneaPagoImpuestosMember 2026-09-30 0001839285 hcti:BankinterMember 2026-09-30 0001839285 hcti:DeutscheTwoMember 2025-12-31 0001839285 hcti:CompensationMember hcti:BoardOfDirectorsMember 2025-07-01 2025-09-30 0001839285 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001839285 hcti:TwoThousandTwentyFiveDebentures1Member 2025-01-01 2025-12-31 0001839285 us-gaap:SeriesBPreferredStockMember 2026-09-30 0001839285 hcti:SecureKloudTechnologiesIncMember hcti:ServicesRenderedMember 2025-07-01 2025-09-30 0001839285 hcti:SecureKloudTechnologiesIncMember hcti:ServicesRenderedMember 2026-01-01 2026-09-30 0001839285 us-gaap:FairValueInputsLevel2Member 2026-09-30 0001839285 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0001839285 hcti:BankiaMember 2026-09-30 0001839285 hcti:AmountsAdvancedMember hcti:SecureKloudTechnologiesIncMember 2025-07-01 2025-09-30 0001839285 hcti:AmountsAdvancedMember hcti:BlockedgeTechnologiesIncMember 2026-01-01 2026-09-30 0001839285 hcti:CommonStockToBeIssuedMember 2025-06-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:SecureKloudTechnologiesIncMember 2025-07-01 2025-09-30 0001839285 hcti:BankinterTwoMember 2026-09-30 0001839285 hcti:AmountsAdvancedMember hcti:HealthcareTrianglePvtLimitedIndiaMember 2025-01-01 2025-09-30 0001839285 hcti:AmountsCollectedByRelatedPartyOnBehalfOfTheCompanyMember hcti:SecureKloudTechnologiesIncMember 2026-07-01 2026-09-30 0001839285 hcti:AmountsAdvancedMember hcti:BlockedgeTechnologiesIncMember 2026-07-01 2026-09-30 0001839285 hcti:BBVAThreeMember 2026-09-30 0001839285 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001839285 hcti:BsantanderOneMember 2025-12-31 0001839285 hcti:BlockedgeTechnologiesIncMember hcti:RevenueMember 2026-01-01 2026-09-30 0001839285 hcti:TargobankMember 2026-09-30 0001839285 hcti:CustomerEngagementServicesMember 2025-01-01 2025-09-30 0001839285 hcti:AmountsAdvancedMember hcti:SecureKloudTechnologiesLimitedIndiaMember 2026-07-01 2026-09-30 0001839285 hcti:CustomerEngagementServicesMember 2025-07-01 2025-09-30 0001839285 hcti:ServicesReceivedAndPaidMember hcti:HealthcareTrianglePvtLimitedIndiaMember 2025-01-01 2025-09-30 0001839285 hcti:BsantanderMember 2026-09-30 0001839285 hcti:BsantanderOneMember 2026-09-30 0001839285 hcti:AmountsAdvancedMember hcti:SecureKloudTechnologiesIncMember 2026-07-01 2026-09-30 0001839285 hcti:BsantanderMember 2025-12-31 0001839285 hcti:TwoThousandTwentySixDebenturesMember 2026-09-30 0001839285 hcti:CompensationMember hcti:BoardOfDirectorsMember 2025-01-01 2025-09-30 0001839285 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0001839285 hcti:BlockedgeTechnologiesIncMember hcti:RevenueMember 2026-07-01 2026-09-30 0001839285 hcti:AmountsAdvancedMember hcti:BoardOfDirectorsMember 2025-01-01 2025-09-30 0001839285 hcti:AmountsCollectedByRelatedPartyOnBehalfOfTheCompanyMember hcti:SecureKloudTechnologiesIncMember 2026-01-01 2026-09-30 0001839285 us-gaap:NoncontrollingInterestMember 2025-06-30 0001839285 hcti:AmountsAdvancedMember hcti:BoardOfDirectorsMember 2025-07-01 2025-09-30 0001839285 hcti:TwoThousandTwentyFiveDebentures1Member 2025-12-31 0001839285 hcti:SecureKloudTechnologiesIncMember hcti:ServicesRenderedMember 2026-07-01 2026-09-30 0001839285 hcti:DeutscheMember 2025-12-31 0001839285 hcti:CaixabankThreeMember 2025-12-31 0001839285 hcti:BankinterTwoMember 2025-12-31 0001839285 hcti:BankinterMember 2025-12-31 0001839285 hcti:BankinterLneaPagoImpuestosMember 2025-12-31 0001839285 hcti:RentExpensesPaidMember hcti:SecureKloudTechnologiesIncMember 2026-07-01 2026-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission file number 001-40903

 

HEALTHCARE TRIANGLE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   84-3559776
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)
     
7901 Stoneridge Drive, Suite 210 Pleasanton, CA   94588
(Address of principal executive offices)   (Zip Code)
     
(925) 270-4812
(Registrant’s telephone number, including area code)

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.00001 par value   HCTI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

 

Yes ☐ No ☒

 

As of November 11, 2026, 915,189 shares of the registrant’s common stock, $0.00001 par value per share, were issued and outstanding.

 

 

 

 

 

 

Table of Contents

 

Note About Forward-Looking Statements   ii
PART I – FINANCIAL INFORMATION   1
Item 1. Financial Statements   1
Unaudited Condensed Consolidated Balance Sheets   1
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss   2
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)   3
Unaudited Condensed Consolidated Statements of Cash Flows   6
Notes to Unaudited Condensed Consolidated Financial Statements   7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   31
Item 3. Quantitative and Qualitative Disclosures About Market Risk   47
Item 4. Controls and Procedures   47
PART II - OTHER INFORMATION   48
Item 1. Legal Proceedings   48
Item 1A. Risk Factors   48
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   48
Item 3. Defaults Upon Senior Securities   48
Item 4. Mine Safety Disclosures   48
Item 5. Other Information   48
Item 6. Exhibits   49
Signatures   50

 

i

 

 

NOTE ABOUT FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, involving substantial risks and uncertainties. The words “believe,” “may,” “will,” “potentially,” “plan,” “could,” “should,” “predict,” “ongoing,” “estimate,” “continue,” “anticipate,” “intend,” “project,” “expect,” “seek,” or the negative of these words, or terms or similar expressions conveying uncertainty of future events or outcomes, or that concern our expectations, strategy, plans or intentions, are intended to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or expected. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on April 15, 2026, as amended, and in our other publicly available filings and press releases. These statements include, among other things, those regarding:

 

  ● our ability to continue to add new customers and increase sales to our existing customers;

 

  ● our ability to develop new solutions and bring them to market in a timely manner;

 

  ● our ability to timely and effectively scale and adapt our existing solutions;

 

  ● our dependence on establishing and maintaining a strong brand;

 

  ● the occurrence of service interruptions and security or privacy breaches and related remediation efforts and fines;

 

  ● system failures or capacity constraints;

 

  ● the rate of growth of, and anticipated trends and challenges in, our business and in the market for our products;

 

  ● our future financial performance, including our expectations regarding our revenue, cost of revenue, operating expenses, including changes in technology and development, marketing and advertising, general and administrative and customer care expenses, and our ability to achieve and maintain future profitability;

 

  ● our ability to continue to efficiently acquire customers, maintain our high customer retention rates and maintain the level of our customers’ lifetime spend;

 

  ● our ability to provide high-quality customer care;

 

  ● the effects of increased competition in our markets and our ability to compete effectively;

 

  ● our ability to grow internationally;

 

  ● the impact of fluctuations in foreign currency exchange rates on our business and our ability to effectively manage the exposure to such fluctuations;

 

  ● our ability to effectively manage our growth and associated investments, including our migration of the vast majority of our infrastructure to the public cloud;

 

  ● our ability to maintain our relationships with our partners;

 

  ● adverse consequences of our substantial level of indebtedness and our ability to repay our debt;

 

  ● our ability to maintain, protect and enhance our intellectual property;

 

ii

 

 

  ● our ability to maintain or improve our market share;

 

  ● our ability to continue generating cashflows and to maintain sufficiency of cash and cash equivalents to meet our needs for at least the next 12 months;

 

  ● beliefs and objectives for future operations;

 

  ● our ability to stay in compliance with laws and regulations currently applicable to, or which may become applicable to, our business both in the United States (U.S.) and internationally;

 

  ● economic and industry trends or trend analysis;

 

  ● our ability to attract and retain qualified employees and key personnel;

 

  ● anticipated income tax rates, tax estimates and tax standards;

 

  ● interest and other embedded rate changes;

 

  ● the future trading prices of our common stock;

 

  ● our expectations regarding the outcome of any regulatory investigation or litigation;

 

  ● the amount and timing of future repurchases of our common stock under any share repurchase program;

 

  ● the potential impact of shareholder activism on our business and operations; and

 

  ● the length and severity of pandemics and their impact on our business, customers and employees; as well as other statements regarding our future operations, financial condition, growth prospects and business strategies.

 

We operate in very competitive and rapidly changing environments, and new risks emerge from time-to-time. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this report may not occur, and actual results could differ materially and adversely from those implied in our forward-looking statements.

 

You should not rely upon forward-looking statements as predictions of future events. Although we believe the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. Neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to publicly update any forward-looking statements for any reason after the date of this report to conform such statements to actual results or to changes in our expectations, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

 

Unless expressly indicated or the context suggests otherwise, references to “Healthcare Triangle,” “company,” “we,” “us” and “our” refer to Healthcare Triangle, Inc. and its consolidated subsidiaries.

 

iii

 

 

PART I

 

FINANCIAL INFORMATION

 

Item 1. Financial statements (In thousands of US $, unless otherwise noted)

 

HEALTHCARE TRIANGLE, INC.

 

Unaudited Condensed Consolidated Balance Sheets

 

          September 30,     December 31,  
    Note     2026     2025  
          (Unaudited)     (Audited)  
Assets                  
Current assets                  
Cash and cash equivalents           $ 1,869     $ 7,625  
Accounts receivable, net     3       4,789       2,070  
Other current assets     4       2,204       3,456  
Total current assets             8,862       13,151  
Advances, net     5       1,975       3,826  
Furniture and equipment, net     7       1,091       5  
Other intangible assets, net     6       55,425       2,808  
Goodwill     6       2,946       2,946  
Operating lease right-of-use assets     8       973       -  
Other non-current assets     9       1,426       -  
Total assets           $ 72,698     $ 22,736  
                         
Liabilities and stockholders’ equity                        
Current liabilities                        
Accounts payable           $ 1,299     $ 744  
Short-term debt     10       9,000       10,737  
Operating lease liabilities – current     8       678       -  
Other current liabilities     11       3,406       1,311  
Total current liabilities             14,383       12,792  
Non-current liabilities                        
Long-term debt     10       2,640       -  
Operating lease liabilities - non-current     8       296       -  
Contingent consideration     6,12       5,000       -  
Other non-current liabilities             141       -  
Total liabilities             22,460       12,792  
Stockholders’ equity     13                  
Preferred stock, par value $0.00001; 10,000,000 authorized:                        
Series A super voting preferred stock - 20,000 shares issued and outstanding as of each of September 30, 2026, and December 31, 2025             -       -  
Series B convertible preferred stock, nil and 1,600,000 shares issued and outstanding as of September 30, 2026, and December 31, 2025, respectively             -       7,435  
Common stock, par value $0.00001; 2,000,000,000 authorized; 886,497 and 7,121 shares issued and outstanding as of September 30, 2026, and December 31, 2025, respectively             -       11  
Additional paid-in capital             102,697       45,534  
Accumulated deficit             (52,311 )     (42,999 )
Total equity attributable to HCTI stockholders             50,386       9,981  
Non-controlling interest             (148 )     (37 )
Total stockholders’ equity             50,238       9,944  
Total liabilities and stockholders’ equity           $ 72,698     $ 22,736  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

1

 

 

HEALTHCARE TRIANGLE, INC.

 

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

 

        Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    Note   2026     2025     2026     2025  
Net revenue       $ 9,116     $ 3,489     $ 28,162     $ 10,752  
Cost of revenue (exclusive of depreciation and amortization shown separately below)         7,035       2,871       21,622       9,310  
Gross margin         2,081       618       6,540       1,442  
Operating expenses                                    
Sales and marketing         1,538       1,022       4,038       2,012  
General and administrative         2,213       2,085       10,251       4,464  
Research and development         231       59       367       257  
Bad debt expense         26       (20 )     168       (20 )
Depreciation and amortization   6,7     74       63       1,413       75  
Total operating expenses         4,082       3,209       16,237       6,788  
Loss from operations         (2,001 )     (2,591 )     (9,697 )     (5,346 )
Other income         190       731       636       854  
Changes in fair value   10     (629 )     -       (3,717 )     -  
Interest expense         (80 )     (32 )     (253 )     (467 )
Forex loss         (26 )     (14 )     (105 )     (14 )
Loss before income tax         (2,546 )     (1,906 )     (13,136 )     (4,973 )
Income tax reversal / (expense)         14       -       (11 )     -  
Net loss       $ (2,532 )   $ (1,906 )   $ (13,147 )   $ (4,973 )
Other comprehensive income (OCI)                                    
Foreign currency translation gain         124       6       197       6  
Comprehensive loss       $ (2,408 )     (1,900 )   $ (12,950 )     (4,967 )
Comprehensive loss attributable to:                                    
Stockholders       $ (2,349 )     (1,882 )   $ (12,839 )     (4,949 )
Non-controlling interest         (59 )     (18 )     (111 )     (18 )
Net (loss) per common share - basic and diluted, attributable to stockholders   17     -       (509.53 )     (36.83 )     (2,683.58 )
Net income per common share - basic attributable to stockholders   17     1.70       -       -       -  
Net income per common share – diluted attributable to stockholders   17     1.21       -       -       -  
Stockholders- Diluted                                    
Weighted average shares outstanding used in per common share computations:                                    
Basic         620,496       3,703       258,212       1,846  
Diluted         872,744       -       -       -  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

2

 

 

HEALTHCARE TRIANGLE, INC.

 

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity

 

    Preferred stock
(Series A)
    Preferred stock
(Series B)
    Preferred stock
(Series C, to be issued)
    Common stock     Additional paid-in     Non-controlling     Accumulated     Total stockholders’  
    Shares     Amount       Shares(*)     Amount     Shares     Amount     Shares     Amount     capital     interest     deficit     equity  
Three months ended September 30, 2026                                                                        
Balance at June 30, 2026     20,000          -       1,600,000       7,435            -       18,000       101,386       11       77,231       (89 )     (53,489 )     49,099  
                                                                                                 
Net loss     -       -       -       -       -       -       -       -       -       (59 )     (2,473 )     (2,532 )
                                                                                                 
Transfer to additional paid-in capital                                                             (11 )     11       -       -       -  
                                                                                                 
Effects of exchange translation reserve (OCI)     -       -       -       -       -       -       -       -       -       -       124       124  
                                                                                                 
Equity line of credit – Hudson shares     -       -       -       -       -       -       2,500       -       -       -       -       -  
                                                                                                 
Common stock issued for cash (ELOC)- gross proceeds     -       -       -       -       -       -       17,500       -       338       -       -       338  
                                                                                                 
Less: ELOC issuance expenses                                                                     (25 )                     (25 )
                                                                                                 
Common stock issued for cash (ATM placements)- gross proceeds received     -       -       -       -       -       -       137,784       -       4,100       -       -       4,100  
                                                                                                 
Less: Placement commission                                                                     (142 )                     (142 )
                                                                                                 
Shares buy back at market(1)     -       -       -       -       -       -       -       -       (98 )     -       -       (98 )
                                                                                                 
Extinguishment and exchange of Series B preferred stock to common equity     -       -       (1,600,000 )     (7,435 )     -       -       141,408       -       3,282       -       3,527       (626 ) 
                                                                                                 
Issuance of stock in connection with business combination     -       -       -       -       -       (18,000 )     485,919       -       18,000                         -       -       -  
                                                                                                 
Balance at September 30, 2026     20,000       -       -       -       -       -       886,497       -       102,697       (148 )     (52,311 )     50,238  

 

(1) During September 2026, pursuant to its previously announced share repurchase program, the Company executed a single transaction to repurchase 127,248 shares of its common stock (equivalent to approximately 6,362 shares following the one-for-twenty reverse stock split effective October 26, 2026, before fractional-share adjustments). As of September 30, 2026, the transfer of these shares to the Company remained pending. Upon completion of the transfer, the Company intends to cancel and retire the repurchased shares.

 

3

 

 

HEALTHCARE TRIANGLE, INC.

 

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity

 

    Preferred stock
(Series A)
    Preferred stock
(Series B)
    Common stock     Additional paid-in     Non-controlling     Accumulated     Total stockholders’  
    Shares     Amount     Shares(*)     Amount     Shares     Amount     capital     interest     deficit     equity  
Nine months ended September 30, 2026                                                            
Balance at December 31, 2025     20,000       -       1,600,000       7,435       7,121       11       45,534       (37 )     (42,999 )     9,944  
                                                                                 
Net loss     -       -       -       -       -       -       -       (111 )     (13,036 )     (13,147 )
                                                                                 
Transfer to additional paid-in capital                                             (11 )      11                

-

 
                                                                                 
Effects of exchange translation reserve (OCI)     -       -       -       -       -       -       -       -       197       197  
                                                                                 
Common stock, pre-funded warrants and preferred stock issued for acquisition(1)       -       -       -       -       488,703       -       30,000       -       -       30,000  
                                                                                 
Common stock issued for cash (ATM placements)- gross proceeds received     -       -       -       -       172,615       -       10,135       -       -       10,135  
                                                                                 
Less: Placement commission     -       -       -       -       -       -      

(322

)     -       -      

(322

)
                                                                                 
Shares buy back at market(3)     -       -       -       -       -       -       (98 )     -       -       (98 )
                                                                                 
Equity line of credit – Hudson shares (2)     -       -       -       -       2,500       -       112       -       -       112  
                                                                                 
Common stock issued for cash (ELOC)     -       -       -       -       17,500       -       338       -       -       338  
                                                                                 
Less: ELOC issuance costs     -       -       -       -        -       -      

(25

)     -       -      

(25

)
                                                                                 
Extinguishment and exchange of Series B preferred stock to common equity     -       -       (1,600,000 )     (7,435 )     141,408       -       3,282       -       3,527       (626 ) 
                                                                                 
Conversion of debt to equity     -       -       -       -       22,572       -       10,167       -       -       10,167  
                                                                                 
Equity issued pursuant to a financing arrangement     -       -       -       -       34,078       -       3,960       -       -       3,960  
                                                                                 
Less: Issuance costs     -       -       -       -               -       (397 )     -       -       (397 )
                                                                                 
Balance at September 30, 2026     20,000       -       -       -       886,497      

-

      102,697       (148 )     (52,311 )     50,238  

 

(*) The reverse stock splits effected in August 2025, February 2026, and October 2026 applied to the Company’s common stock and did not affect the number of Series ‘A’ or Series ‘B’ Preferred Stock shares outstanding. Also see note 13.
   
(1) See note 6(B) for details on common stock and pre-funded warrants issued in connection with the acquisition. 
   
(2) See note 13(A)(ii) for details on equity line of credit – prefunded warrants.
   
(3)

During September 2026, pursuant to its previously announced share repurchase program, the Company executed a single transaction to repurchase 127,248 shares of its common stock (equivalent to approximately 6,362 shares following the one-for-twenty reverse stock split effective October 26, 2026, before fractional-share adjustments). As of September 30, 2026, the transfer of these shares to the Company remained pending. Upon completion of the transfer, the Company intends to cancel and retire the repurchased shares.

4

 

 

HEALTHCARE TRIANGLE, INC.

 

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity

 

    Preferred stock
(Series A)
    Preferred stock
(Series B)
    Common stock     Additional
paid-in
    Equity
to be
    Non-controlling     Accumulated     Total
stockholders’
equity
 
    Shares     Amount     Shares     Amount     Shares     Amount     capital     issued     Interest     deficit     (deficit)  
Three months ended September 30, 2025                                                                  
Balance at June 30, 2025     20,000     $        -       1,600,000     $ 7,435       4,860     $ 14     $ 39,399       -       -     $ (36,638 )   $ 10,210  
Net loss     -       -       -       -       -       -       -       -       (18 )     (1,888 )     (1,906 )
Effects of exchange translation reserve (OCI)     -       -       -       -       -       -       -       -       -       6       6  
Issue of Options (ISO/NSO)     -       -       -       -       -       -       416       -       -       -       416  
Cancellation of shares     -       -       -       -       (1,157 )     (3 )     (2,997 )     -       -       -       (3,000 )
Shares to be issued     -       -       -       -       -       -       -       3,000       -       -       3,000  
Balance at September 30, 2025     20,000     $ -       1,600,000     $ 7,435       3,703     $ 11     $ 36,818     $ 3,000     $ (18 )   $ (38,520 )   $ 8,726  
                                                                                         
Nine months ended September 30, 2025                                                                                        
Balance at December 31, 2024     6,000               1,600,000       7,435       19       0       21,022       -       -       (33,571 )     (5,114 )
Net loss     -       -       -       -       -       -       -       -       (18 )     (4,955 )     (4,973 )
Shares issued for services     14,000       -       -       -       -       -       88       -       -       -       88  
Effects of exchange translation reserve     -       -       -       -       -       -       -       -              -       6       6  
Common stock issued for cash     -       -       -       -       23       -       95       -       -       -       95  
Prefunded warrants issued for cash     -       -       -       -       98       -       395       -       -       -       395  
Series B (cashless warrants)     -       -       -       -       3,552       11       14,699       -       -       -       14,710  
Expenses relating to funding     -       -       -       -       -       -       (1,524 )     -       -       -       (1,524 )
Shares issued for acquisition     -       -       -       -       1,157       3       2,997       -       -       -       3,000  
Conversion of Debt to Equity     -       -       -       -       9       -       1,191       -       -       -       1,191  
Shares issued for acquisition (contingent consideration)     -       -       -       -       2       -       400       -       -       -       400  
Stock based compensation     -       -       -       -       -       -       452       -       -       -       452  
Cancellation of shares     -       -       -       -       (1,157 )     (3 )     (2,997 )     -       -       -       (3,000 )
Shares to be issued     -       -       -       -       -       -       -       3,000       -       -       3,000  
Balance at September 30, 2025     20,000       -       1,600,000     $ 7,435       3,703     $ 11     $ 36,818     $ 3,000     $ (18 )   $ (38,520 )   $ 8,726  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5

 

 

HEALTHCARE TRIANGLE, INC.

 

Unaudited Condensed Consolidated Statements of Cash Flows

 

          Nine Months Ended
September 30,
 
    Note     2026     2025  
          (In ’000)  
Cash flows from operating activities                  
Net loss           $ (13,147 )   $ (4,973 )
Adjustment to reconcile net loss to net cash provided by / (used in) operating activities                        
Depreciation and amortization             1,413       75  
Net unrealized exchange loss             105       8  
Change in fair value             3,717       -  
Common stock issued for services             -       88  
Amortization of debt discount             -       223  
Other income             (7 )     (683 )
Stock compensation expenses             -       451  
Interest expenses             253       467  
Interest expenses settled by equity             -       316  
Right-of-use lease expenses             618       -  
Bad debt expense     3       168       (20 )
Changes in working capital:                        
Accounts receivable             1,984       (1,247 )
Other current assets             (1,027 )     (40 )
Due from affiliates             -       (3,005 )
Accounts payable             (2,278 )     (1,377 )
Other current liabilities             (1,159 )     28  
Payment of lease liability     8       (594 )     -  
Interest paid             (253 )     (467 )*
Net cash used in operating activities             (10,207 )     (10,156 )
                         
Cash flows from investing activities                        
Purchase of furniture and equipment             (108 )     (6 )
Disposal of furniture and equipment             7       -  
Acquisition of intangible assets             -       (1,283 )
Acquisition of Teyame, net of cash acquired on business combination     6       (10,598 )     -  
Net cash used in investing activities             (10,699 )     (1,289 )
                         
Cash flows from financing activities                        
Proceeds from debt     10       112,391       -  
Decrease in short term borrowing     10       (7 )     (1,251 )
Repayment of debt     10       (110,806 )     -  
Proceeds from equity issuance             13,688       14,305  
Share buy-back at market             (98 )     -  
Net cash provided by financing activities             15,168       13,054  
                         
Effect of exchange rate changes on cash and cash equivalents             (18 )     -  
                         
Net (decrease)/increase in cash and cash equivalents             (5,756 )     1,609  
                         
Cash and cash equivalents                        
Cash and cash equivalents at the beginning of the year             7,625       20  
Cash and cash equivalents at the end of the period           $ 1,869     $ 1,629  
                         
Supplementary disclosure of cash flows information                        
Deferred offering cost           $ 110     $ -  
Investment in platform development work-in-progress             1,225       -  
Conversion of debt to common stock             10,167       -  
Acquisition of Teyame     6 (B)     39,400       -  
Settlement of Series B convertible preferred stock (including advance settlement of $626)     13 (B)     7,435       -  
Equity to be issued             -       3,000  
Operating right-of-use asset             973       -  
Acquisition of assets           $ -     $ 1,200  

 

(*) Corresponding figures have been rearranged for the purposes of comparison.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

6

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

Organization and Description of Business

 

Healthcare Triangle, Inc. (“HTI” or “the Company”) was incorporated under the laws of the State of Nevada on October 29, 2019, and converted into a Delaware corporation on April 24, 2020, to provide IT and data services to the Healthcare and Life Sciences (“HCLS”) industry. On January 1, 2020, the Company acquired the Life Sciences Business of SecureKloud Technologies Inc. and on May 8, 2020, the Company acquired Cornerstone Advisors Group LLC (Healthcare Business) from SecureKloud.

 

During 2025, the Company, through its wholly owned subsidiary QuantumNexis Inc., a Delaware corporation, entered into an Asset and Stock Transfer Agreement (ATA) with Niyama Healthcare Inc., a provider of Mental Health and Hospital Information Systems technology, across India, Southeast Asia, and Europe (the “Seller”). Pursuant to the ATA, the Company purchased (i) the Transferred Assets (comprising of contracts, intellectual property and related assets), and (ii) 100% shareholder equity interest in Ezovion Solutions Private Limited, Chennai, India - a Hospital Information Systems SaaS Provider in exchange for a Purchase Price.

 

Effective January 1, 2026, the Company, through its wholly owned subsidiary Teyame AI Holdings Inc., a Delaware corporation, acquired Teyame 360 S.L. (“Teyame”) and Datono Mediacion S.L. (“Datono”) (see note 6[B] for details). Together, Teyame and Datono operate as an integrated platform providing AI-powered omnichannel customer experience, marketing, financial and insurance distribution services.

 

Teyame leverages its technology solutions to provide customer engagement services that combine artificial intelligence, telemarketing, and contact center operations to support customer acquisition, retention, and service. Its platform enables enterprises particularly in financial services, insurance, and healthcare to manage end-to-end customer interactions across multiple channels.

 

Datono complements this platform as an insurance brokerage entity, facilitating the marketing and sales of insurance products. Together, the companies form a vertically integrated model combining customer acquisition technology with distribution capabilities, particularly in regulated sectors such as insurance.

 

Liquidity Risk

 

The Company incurred loss from operations of $9,697, had negative operating cash flows of $10,207, and an accumulated deficit of $52,311 as of September 30, 2026. Management evaluated these conditions and concluded that they have been sufficiently mitigated by the Company’s net assets of $50,238 (including cash and cash equivalents of $1,869) at September 30, 2026, and the presence of an Equity Line of Credit pursuant to which the Company can elect to issue shares of its common stock up to a value of $50,000 (see note 13(D)[iii]). In addition, the Company continues to have access to its At-the-Market Sales Agreement dated November 18, 2025, pursuant to which the Company can issue its common stock at market prices. Accordingly, management has concluded that the Company has sufficient resources to fund operations and meet its obligations as they become due for a period of at least twelve months from the date these unaudited condensed consolidated financial statements are issued.

 

1) Basis of Preparation of Unaudited Condensed Consolidated Financial Statements

 

These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Securities and Exchange Commission, or SEC, Regulation S-X. The December 31, 2025, consolidated balance sheet was derived from our audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, but does not include all disclosures required by U.S. GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of items of a normal and recurring nature, necessary to present fairly our financial position as of September 30, 2026, the results of operations, comprehensive loss, and stockholders’ equity (deficit) for the three and nine months ended September 30, 2026, and 2025, and cash flows for the nine months ended September 30, 2026, and 2025. The results of operations for the periods presented are not necessarily indicative of the results to be expected for any future period. The information contained herein should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC. Management considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date of issuance of these condensed consolidated financial statements.

 

All intercompany balances and transactions have been eliminated upon consolidation.

 

Certain balances from the prior fiscal year have been reclassified to conform to the current period presentation.

 

7

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

2) Summary of Significant Accounting Policies

 

Revenue Recognition

 

We recognize revenues as we transfer control of deliverables (services, solutions, and platform) to our clients in an amount reflecting the consideration to which we expect to be entitled. To recognize revenues, we apply the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenues when a performance obligation is satisfied. We account for a contract when it has approval and commitment from all parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. We apply judgment in determining the customer’s ability and intention to pay based on factors including historical payment experience, credit profile, and geographic and industry risk factors. For customers acquired through business combinations, collectability is assessed using the acquired entity’s collection history with those customers, supplemented by post-acquisition payment performance. A contract is recognized only where collectability of substantially all consideration is probable.

 

For performance obligations where control is transferred over time, revenues are recognized based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the deliverables to be provided.

 

The Company accounts for revenue from a contract after it is approved by the customer, and after ensuring that the rights of each party regarding the services to be transferred, the payment terms, the commercial substance, and the collectability are ascertained. In assessing collectability, the Company applies judgment and considers factors such as the customer’s credit profile, past payment behavior, and the nature and geography of the customer relationship.

 

Contract modifications, such as changes in scope, rates, or duration, are assessed to determine whether they should be accounted for as a separate contract or as part of the existing contract. A modification is treated as a separate contract when it adds services at a price that reflects their standalone selling price. Otherwise, the modification is combined with the existing contract, and the transaction price is updated on a prospective or cumulative catch-up basis, as appropriate.

 

When it becomes probable that total costs to satisfy a contract will exceed the transaction price, the expected loss is recognized in full in the period in which the loss becomes probable and can be reasonably estimated, regardless of whether work has commenced under the contract.

 

8

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

Revenue is earned and recognized in the following segments:

 

A. Software Services

 

The Company enters into contractual obligations with the customers to perform (i) Strategic advisory services which include assessment of the enterprise network, applications environment and advise on the design and tools; (ii) Implementation services which include deployment, upgrades, enhancements, migration, training, documentation and maintenance of various electronic health record systems and (iii) Development services which include customization of network and applications in the public cloud environment.

 

Revenue from Strategic advisory, Implementation and Development services are distinct performance obligation and is recognized on time-and-material or fixed-price project basis. Revenues related to time-and-material are recognized over the period the services are provided using labor hours. Revenues related to fixed-price contracts are recognized as the service is performed using the cost-to-cost method, under which the total value of revenues is recognized based on the percentage that each contract’s total labor cost to date bears to the total expected labor costs. The cost-to-cost method requires estimation of future costs, which is updated as the project progresses to reflect the latest available information; such estimates and changes in estimates involve the use of judgment. The cumulative impact of any revision in estimates is reflected in the financial reporting period in which the change in estimate becomes known and any anticipated losses on contracts are recognized immediately, where appropriate.

 

We may enter into contracts that consist of multiple performance obligations. Such contracts may include any combination of our deliverables. To the extent a contract includes multiple promised deliverables, we apply judgment to determine whether promised deliverables are capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised deliverables are accounted for as a combined performance obligation. For contracts with multiple distinct performance obligations, we allocate consideration among the performance obligations based on their relative standalone selling price. Standalone selling price is the price at which we would sell a promised good or service separately to the customer. When not directly observable, we estimate standalone selling price by using the expected cost plus a margin approach. We establish a standalone selling price range for our deliverables, which is reassessed on a periodic basis or when facts and circumstances change.

 

Contract modifications, such as extensions of statement of work duration or changes in resources and rates, are evaluated under ASC 606 and accounted for prospectively as a separate contract or modification of the existing contract, based on whether the modification adds distinct performance obligations at standalone selling prices.

 

When the estimated costs to complete a performance obligation exceed the expected transaction price, the full amount of the anticipated loss is recognized immediately in the period in which the loss becomes probable and estimable.

 

Certain contracts include variable consideration such as rate adjustments, which is estimated using the most likely amount method and included in the transaction price only to the extent that a significant revenue reversal is not probable. Estimates are reassessed at each reporting date.

 

9

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

B. Managed Services and Support

 

The Company has standard contracts for its Managed Services and Support, however the statement of work contained in such contracts is unique for each customer. A typical Managed Services and Support contract would provide for some or all of the following types of services being provided to the customer: Cloud hosting, Continuous monitoring of applications, security and compliance and support.

 

Revenue from Managed services and support is a distinct performance obligation and recognized based on Standalone Selling Price (SSP), ratably on a straight-line basis over the period in which the services are rendered. Contract with customers includes subcontractor services or third-party cloud infrastructure services in certain integrated services arrangements. In these types of arrangements, revenue is recognized net of costs when the Company is acting as an agent between the customer and the vendor, and gross when the Company is the principal for the transaction. In doing so, the Company first evaluates whether it controls the platform or service before it is transferred to the customer. The Company considers whether it has the primary obligation to fulfil the contract, pricing discretion and other factors to determine whether it controls the platform or service and therefore is acting as principal or agent.

 

C. Customer Engagement Services

 

The Customer Engagement Services segment, acquired through business combination (see note 6), provides customer search, marketing, telemarketing and customer-support services to financial institutions, insurance companies and intermediaries, and other customers. These services include the promotion and distribution of banking, credit and insurance products; outbound and inbound telemarketing; lead generation and customer-search campaigns; appointment setting; customer service and satisfaction surveys; and technology-enabled digital marketing and customer-interaction services supporting customers’ digital search and customer-care strategies.

 

The Company recognizes revenue from Customer Engagement Services in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized when or as the Company satisfies its performance obligations by transferring the promised services to the customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those services.

 

Under these arrangements, the Company generally performs the customer-engagement services using its own personnel, processes, systems and operational infrastructure and is primarily responsible for fulfilling the promised services in accordance with contractual requirements and applicable quality standards. The Company has determined that it controls the specified services before they are transferred to the customer and, accordingly, acts as the principal in these arrangements and recognizes revenue on a gross basis.

 

Consideration under Customer Engagement Services arrangements is generally based on either a fee for each completed and validated outcome or an agreed hourly rate for services provided.

 

For success-based arrangements, revenue is recognized at a point in time when the applicable contractual outcome has been completed and validated by the customer in accordance with contractual terms. To the extent such consideration is variable, revenue is recognized only to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur.

 

For hourly service arrangements, revenue is recognized over time as the services are performed because the customer simultaneously receives and consumes the benefits of the Company’s performance. Revenue is measured based on the contracted hourly rate and the actual hours of service provided during the applicable reporting period.

 

Revenue is presented net of estimated cancellations, penalties and other adjustments to the extent such amounts represent adjustments to the transaction price under the applicable customer contracts.

 

D. All others

 

This segment includes Platform Services revenue. A typical Platform Services contract would provide for some or all of the following types of services being provided to the customer: Data Analytics, Backup and Recovery, through our Platform with contract terms unique to each customer. The Company delivers Platform Services through its proprietary platform. Where third-party technology or infrastructure is included in the arrangement, the Company evaluates whether it is acting as principal or agent based on whether it controls the service before transfer to the customer.

 

10

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

The revenue from Platform Services is a distinct performance obligation and recognized based on SSP. During the periods presented the Company generated revenue from Platform Services on a fixed-price solutions delivery model. Revenues related to fixed-price contracts are recognized as the service is performed using the cost-to-cost method, under which the total value of revenues is recognized based on the percentage that each contract’s total labor cost to date bears to the total expected labor costs. The cost-to-cost method requires estimation of future costs, which is updated as the project progresses to reflect the latest available information; such estimates and changes in estimates involve the use of judgment. The cumulative impact of any revision in estimates is reflected in the financial reporting period in which the change in estimate becomes known and any anticipated losses on contracts are recognized in full in the period in which the loss becomes probable and estimable.

 

Our contractual terms and conditions for revenue mandate that our services are documented and subject to inspection, testing at the time of delivery to customer. In addition, the Company needs to integrate seamlessly into the customers’ systems. Also, the customer has a right to cancel all, or part of the services rendered if it is not in accordance with statement of work and within the stipulated time.

 

Fair Value Measurements

 

    September 30, 2026  
    Fair Value Measured Using  
    Level 1     Level 2     Level 3     Total  
Financial Assets:                        
Cash and cash equivalents   $ 1,869       —       —     $ 1,869  
Financial liabilities:                                
2026 Convertible Notes (refer note 10[C])     —       —     $ 3,602     $ 3,602  
Contingent consideration     —       —     $ 5,000     $ 5,000  

 

    December 31, 2025  
    Fair Value Measured Using  
    Level 1     Level 2     Level 3     Total  
Financial Assets:                        
Cash and cash equivalents   $ 7,625       —       —     $ 7,625  
Financial liabilities:                                
2025 Convertible Notes (refer note 10[B])   $ —       —       10,543 *   $ 10,543  

 

(*) Corresponding figures have been rearranged for the purposes of comparison.

 

Concentration

 

The Company monitors the credit worthiness of its customers through various factors, including review of their financial statements and other associated information. For the quarters ended September 30, 2026, and 2025, sales to five major customers accounted for approximately 58% and 56% of total revenue respectively. As of September 30, 2026, and December 31, 2025, accounts receivable from five major customers accounted for approximately 52% and 51% of the total accounts receivable.

 

As of September 30, 2026, and December 31, 2025, the Company had $710 and $6,503 respectively, of uninsured cash balances. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash.

 

11

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

3) Accounts Receivable, net

 

    September 30,
2026
    December 31,
2025
 
Accounts receivable, gross   $ 5,137     $      2,272  
Less: Allowance for doubtful accounts (current expected credit loss) – see 3.1 below     (348 )     (202 )
Accounts receivable, net   $ 4,789     $ 2,070  

 

3.1) Current Expected Credit Loss movement*:

 

    September 30,
2026
    December 31,
2025
 
Opening balance   $ 202     $ 185  
Charge for the period / year     168       17  
Adjustment during the period / year     (22 )     -  
Closing balance   $ 348     $ 202  

 

* During the quarter ended September 30, 2026, and year ended December 31, 2025, the Company collected nil and $117 respectively. In addition, accounts receivable amounting to $22 (including $4 cumulative translation adjustment) were deemed uncollectible and adjusted against provision of current expected credit loss as of September 30, 2026.

 

4) Other current assets

 

    September 30,
2026
    December 31,
2025
 
Unbilled revenue   $ 1,407     $     3 *
Prepaid expenses     212       267  
Advance to acquire Teyame and Datono (see note 6[B] for details)     -       3,000  
Deposits     164       -  
Advance to Healthcare Triangle Private Limited, a related party1     60       -  
Others     361       186  
Total   $ 2,204     $ 3,456  

 

* Corresponding figures have been rearranged for the purposes of comparison.
1 The advance is unsecured, non-interest bearing and is expected to be settled in the ordinary course of business, as and when the services are provided.

 

5) Advances

 

    September 30,
2026
    December 31,
2025
 
Advance to related party contractor - for AI tools and software development   $ 1,975     $ 3,200  
Advance to related party contractor - for services     626       626  
      2,601       3,826  
Less: Settlement of advances through equity     (626 )     -  
Total advances, net   $ 1,975     $ 3,826  

 

As of September 30, 2026, and December 31, 2025, the advances outstanding are $1,975, and $3,826 respectively. The balances are unsecured, non-interest bearing and are expected to be settled in the ordinary course of business, as outlined below:

 

  - $3,200 was advanced to SecureKloud Technologies Ltd. in connection with the design, develop and deliver an Integrated Health Advisory & Care Platform & Tools including certain artificial intelligence-enabled software tools and related intellectual property, intended to support the Company’s current and future product offerings, During the period ended September 30, 2026, progress billings amounting to $1,225 were transferred to platform work-in-progress (See note 9), and accordingly, a balance of $1,975 remained as advance as of September 30, 2026.

 

12

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

  - On June 24, 2026, the Company entered into a Securities Exchange Agreement with SecureKloud pursuant to which certain preferred equity securities held by SecureKloud were exchanged for shares of the Company’s common stock on July 28, 2026, following receipt of stockholder approval. In connection with the July 28, 2026, exchange and extinguishment of the Series B Convertible Preferred Stock, the Company assessed the qualitative nature and integrated terms of its settlement with SecureKloud, a related party, and concluded that settlement of the $626 advance represented consideration transferred in the equity exchange rather than a separate settlement expense. Accordingly, the Company reversed the $626 provision during the period ended September 30, 2026, and included the advance settlement in the consideration accounted for directly within stockholders’ equity. The adjustment reduced third-quarter expense and the deemed contribution arising from the preferred-stock extinguishment by $626 each. The combined adjustment was non-cash and had no effect on total stockholders’ equity at September 30, 2026. Management evaluated the quantitative and qualitative effects, including the nature of the transaction and its effects on earnings and earnings per share, and concluded that the matter was not material to the previously issued interim financial statements for the three and six months ended June 30, 2026, and that recognition of the adjustment in the third quarter did not materially affect the interim financial statements for the three and nine months ended September 30, 2026. See also note 13(B).

 

  A. Related party transactions:

 

Following are the transactions with related parties during the periods presented:

 

Related Parties   Nature of transactions   Quarter
ended
September 30,
2026
    Quarter
ended
September 30,
2025
    Nine-months
ended
September 30,
2026
    Nine-months
ended
September 30,
2025
 
SecureKloud Technologies Limited, India   Services received and paid for   $ 1,225     $ 470     $ 1,225     $ 1,945  
    Amounts advanced     -       525       -       2,793  
Healthcare Triangle (Pvt.) Limited, India   Services received and paid for     530       -       1,611       -  
    Amounts advanced     -       -       60       -  
SecureKloud Technologies, Inc.   Services received and paid for     -       -       -       269  
    Amounts advanced     -       -       -       1,666  
    Services rendered     -       -       -       138  
    Amounts collected by related party on behalf of the Company     -       27       -       407  
    Rent expenses paid     -       44       -       133  
Blockedge Technologies, Inc.   Services received and paid for     60       40       180       70  
    Amounts advanced     -       140       -       285  
    Revenue     -       9       -       9  
Key management personnel   Remuneration     309       133       881       385  
Board of Directors   Compensation     55       -       165       -  
    Amount advanced   $ 40       -     $ 40       -  

 

During the period ended September 30, 2026, the Company issued 1,781,745 shares (89,087 shares, subsequent to one-for-twenty reverse stock-split effective October 26, 2026) of common stock to Blockedge Technologies Inc., a subsidiary of SecureKloud Technologies Limited, India, and 1,046,422 shares (52,321 shares, subsequent to one-for-twenty reverse stock-split effective October 26, 2026) to Robinson Vincent, on behalf of SecureKloud Technologies Limited, India, in connection with extinguishment of 1,600,000 Preferred B stock previously held by SecureKloud Technologies Limited, India.

 

13

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

6) Goodwill and Other Intangible Assets

 

    September 30,
2026
    December 31,
2025
 
Goodwill   (see ‘A’ below)   $ 2,946     $ 2,946  
                     
Other intangible assets, net   (see ‘B and C’ below)   $ 55,425     $ 2,808  

  

  A) On June 16, 2025 (the “Closing date”), Healthcare Triangle, Inc. (the “Company”), through its wholly owned subsidiary QuantumNexis Inc., a Delaware corporation, entered into an Asset and Stock Transfer Agreement (ATA) with Niyama Healthcare Inc., a provider of Mental Health and Hospital Information Systems technology, across India, Southeast Asia, and Europe (the “Seller”). Pursuant to the ATA, the Company agreed to purchase (i) the Transferred Assets (comprising of contracts, intellectual property and related assets), and (ii) 100% shareholder equity interest in Ezovion Solutions Private Limited, Chennai, India - Hospital Information Systems SaaS Provider (the “Transferred Equity”), as a whole and as a going concern in exchange for the Purchase Price, which comprised the following:

 

(1) $1,494 in cash, (2) $4,601 in equity consideration; and (3) up to $1,200 (having a fair value of nil as of September 30, 2026, and December 31, 2025) in earn-out payments contingent on first-year financial performance targets to be agreed mutually.

 

The transaction resulted in recognition of goodwill with a carrying value of $2,946, as of September 30, 2026, and December 31, 2025. There are no impairment indicators as at September 30, 2026, and December 31, 2025.

 

  B) On January 22, 2026, Healthcare Triangle, Inc. entered into a share purchase agreement to acquire Teyame 360 S.L. (“Teyame”) and Datono Mediacion S.L. (“Datono”) through its wholly owned subsidiary Teyame AI Holdings Inc., effective January 1, 2026. The aggregate purchase price for the Acquired Companies is up to $50,000, subject to the terms and conditions set forth in the Share Purchase Agreement. The consideration consists of a cash payout of $15,000, with the balance settled through issuance of a combination of the Company’s common stock, preferred stock, with an additional earnout component payable in the Company’s preferred stock upon achievement of specified post-closing performance targets.

 

The cash consideration includes: (i) $3,000 paid during 2025 pursuant to an advance agreement dated December 3, 2025, (ii) $6,000 paid during January 2026, (iii) $3,200 paid during April 2026, (iv)$1,400 paid during September 2026, and (v) $1,400 payable on the earlier of the conditions being met as outlined in the Share Purchase Agreement, or nine months from the date of the Share Purchase Agreement (but in no event prior to April 29, 2026).

 

The equity consideration includes: (a) restricted shares or pre-funded warrants of the Company’s common stock with an agreed value of $12,000, and (b) a series of the Company’s preferred stock with an agreed value of $18,000 that is convertible into the Company’s common stock, subject to stockholders’ approval. During the period ended September 30, 2026, a total of 488,703 shares of common equity (9,774,055 shares prior to the reverse split of 1:20 effected on October 26, 2026), were issued towards the full settlement of the purchase considerations of $12,000 and $18,000 respectively.

 

The number of shares of common stock issued as part of the equity consideration, and the number of shares of common stock underlying the preferred stock, were determined by reference to a “Base Price” equal to the average of the volume-weighted average prices (“VWAPs”) of the Company’s common stock for the five trading days immediately prior to the Closing Date, as further defined in the Share Purchase Agreement. The preferred stocks were converted into common stock subsequent to the stockholder approval on July 17, 2026, as contemplated by the Share Purchase Agreement.

  

14

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

The Share Purchase Agreement also provides for an earnout payable in the Company’s preferred stock to the previous owners of the Acquired Companies, with an aggregate value of up to $5,000, subject to achievement of specified annual targets as outlined in the Share Purchase Agreement.

 

Purchase consideration   Amount  
Cash paid up to September 30, 2026   $ 13,600  
Purchase consideration payable as of September 30, 2026     1,400  
Common stock     12,000  
Preferred stock (convertible into common stock at the Company’s option)     18,000  
Earnout consideration     5,000  
Total   $ 50,000  

 

The Company is in the process of determining the fair values of the identifiable assets acquired and liabilities assumed as of the acquisition date in accordance with ASC 805, Business Combinations. As the initial accounting for the business combination is incomplete as of the date of these financial statements, the Company has not yet finalized the purchase price allocation. The provisional amounts recognized reflect management’s best estimates based on information available at this time.

 

The final purchase price allocation, including the determination of fair values of identifiable intangible assets, property and equipment, deferred tax assets and liabilities, and any resulting goodwill, will be completed as soon as practicable and within the measurement period of up to one year from the acquisition date as permitted under ASC 805-10-25-15. Any adjustments to the provisional amounts identified during the measurement period will be recognized in the reporting period in which the adjustment is determined, with a corresponding adjustment to goodwill.

 

Pending the purchase price allocation, the Company has provisionally recognized an amount of $53,547 as of January 1, 2026, as follows:

 

Current assets acquired:          
Cash and cash equivalents       $ 2  
Accounts receivable, net         4,998  
Other current assets         650  
Total current assets       $ 5,650  
Non-current assets acquired:            
Furniture and equipment, net       $ 1,494  
Operating lease right-of-use assets         1,419  
Other non-current assets         206  
Total assets acquired   (a)   $ 8,769  
             
Liabilities assumed:            
Accounts payable       $ 2,874  
Operating lease liabilities         749  
Short-term borrowing         5,659  
Other current liabilities         1,875  
Total current liabilities       $ 11,157  
Non-current liabilities assumed            
Long term debt         367  
Operating long-term lease liabilities         646  
Other non-current liabilities         146  
Total liabilities assumed   (b)     12,316  
Net liabilities assumed   (c = a – b)   $ (3,547 )
             
Preliminary intangible assets   (d)   $ 53,547  
Total purchase consideration allocated (pending purchase price allocation)   (c + d)   $ 50,000  

 

15

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

  C) Other intangible assets

 

          September 30, 2026     December 31, 2025  
    Useful     Gross     Amortization           Net     Gross     Amortization           Net  
    life     carrying     expense for     Accumulated     carrying     Carrying     expense for     Accumulated     carrying  
    (Years)     amount     the period     amortization     amount     amount     the year     amortization     amount  
Intellectual property   3     $ 3,403     $ 911     $ 1,571     $ 1,832     $ 3,402     $ 660     $ 660     $ 2,742  
Trademark   3       81       20       35       46       81       15       15       66  
Software   3       35       —       35       —       35       17       35       —  
Intangible assets, total         $ 3,519     $ 931     $ 1,641     $ 1,878     $ 3,518     $ 692     $ 710     $ 2,808  

 

7) Furniture and Equipment

 

Furniture and equipment consisted of the following:

 

          September 30, 2026     December 31, 2025  
    Useful     Gross     Depreciation           Net     Gross     Depreciation           Net  
    life     carrying     expense for     Accumulated     carrying     carrying     expense for     Accumulated     carrying  
    (Years)     amount     the period     depreciation     amount     amount     the year     depreciation     amount  
Furniture and Fixtures     3     $ 1,635     $       482     $        544     $ 1,091     $       67     $             5     $           62     $          5  
Furniture and Fixtures total           $ 1,635     $ 482     $ 544     $ 1,091     $ 67     $ 5     $ 62     $ 5  

 

During the period ended September 30, 2026, the Company purchased furniture and fixtures amounting to $108 and disposed of furniture and fixtures costing $34 with a nil book value for $7 resulting in a gain on disposal. In addition, the Company acquired furniture and equipment with a cost of $5,317 and accumulated depreciation of $3,823 as part of the business combination (see note 6[B] for details). Cumulative translation adjustment of $34 has been adjusted in the gross carrying amount as of September 30, 2026.

 

8) Right-of-use Assets

 

The Company determines if an arrangement contains a lease at inception. Right-of-use (“ROU”) assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.

 

The Company utilized a portfolio approach in determining the discount rate. The portfolio approach takes into consideration the range of the term, the range of the lease payments, the category of the underlying asset and the Company’s estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of lease payments. The Company also considered its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating the incremental borrowing rates.

 

Leases with a term of 12 months or less are not recorded on the balance sheet, per the election of the practical expedient. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company recognizes variable lease payments in the period in which the obligation for those payments is incurred. Variable lease payments that depend on an index or a rate are initially measured using the index or rate at the commencement date, otherwise variable lease payments are recognized in the period incurred.

 

ROU Asset:

 

    September 30,
2026
    December 31,
2025
 
       
Operating right-of-use assets, at cost   $ 5,804     $            -  
Less: Accumulated amortization (*)     (4,831 )     -  
Operating right-of-use assets, net   $ 973     $ -  

 

(*) includes operating right-of-use assets acquired as part of business combination – see note 6(B) above, and cumulative translation adjustment of $176.

 

16

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

The Company’s principal facility is located in Pleasanton, CA. Lease rental for the quarter and nine months ended September 30, 2026, were $17 and $54 respectively, whereas rental expenses for the quarter and nine months ended September 30, 2025, were $44 and $133 respectively. The amortization of the ROU asset for the quarter and nine months ended September 30, 2026, were $11 and $27 respectively.

 

In addition, the Company acquired right-of-use assets and lease liability as part of the business combination (see note 6[B] for details). The Company acquired right-of-use assets with a cost of $5,282 and accumulated depreciation of $3,863 as part of the business combination (see note 6[B] for details). The lease relates to an office building located at Calle Rufino González 21, 28037 Madrid, a vehicle and a parking space. The lease terms are 84 months for the building, 48 months for the vehicle and 15 months for the parking space. The leases were measured using provisional discount rates of 1.50% for building 6.99% for vehicle and 5.24% for parking space, resulting in lease liabilities of $661 for the building, $45 for vehicle and $101 for parking space as of September 30, 2026. Lease rental expense for the quarter ended and nine months ended September 30, 2026, were $212 and $640 respectively.

 

Lease liability:

 

Future minimum lease obligations under our non-cancellable lease agreement as of September 30, 2026, and December 31, 2025, are as follows:

 

Fiscal Year   September 30,
2026
    December 31,
2025
 
Next 12 months   $ 717              -  
12-24 months     250       -  
Beyond 24 months     51       -  
Total     1,018       -  
Less: Imputed interest     (44 )     -  
Net present value of future minimum lease payments     974       -  
Less: Operating lease liability, current     (678 )     -  
Operating lease liability, non-current   $ 296       -  

 

    September 30,
2026
    December 31,
2025
 
             
Operating lease liability, current   $ 678                -  
Operating lease liability, non-current   $ 296       -  

 

17

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

9) Other non-current assets

 

    September 30,
2026
    December 31,
2025
 
Platform development work-in-progress (see note 5)     $ 1,225     $                -  
Others     201       -  
Total   $ 1,426     $ -  

 

10) Short-Term Debt

 

    September 30,
2026
    December 31,
2025
 
Recourse financing [refer 10(A) below]   $ 252     $ 161  
Convertible notes [refer 10(B) and 10(C) below]     3,602       10,543  
Debt with credit institutions – current [refer 10(D) below]     5,142       -  
Others     4       33  
Total   $ 9,000     $ 10,737  

 

A. Recourse Financing

 

During 2022, the Company obtained a credit facility from Seacoast Business Funding (SBF), a division of Seacoast National Bank. The funding is against the accounts receivable of the Company and one of its subsidiaries. The maximum amount of advance under the arrangement is $10,000 and the bank may advance up to 90% of the unpaid domestic outstanding accounts under the recourse agreement.

 

The SBF facility incurred a factoring interest cost of 8.5% during the nine months ended September 30, 2026, amounting to $19 and 8.5% for the year ended December 31, 2025, amounting to $81. Cash advances received from such arrangement during the period ended September 30, 2026, and year ended December 31, 2025, were $8,870 and $9,633 respectively. The carrying amount of associated recourse financing liability was $252 and $161, as of September 30, 2026, and December 31, 2025, respectively.

 

In addition, a recently acquired subsidiary of the Company with an acquisition effective date of January 1, 2026, utilizes recourse-based accounts receivable financing arrangement with a number of banks, whereby the subsidiary receives cash against the customer invoices. Under this arrangement, the maximum advance amount available to the subsidiary is $4,118, subject to invoice ageing and related terms. As the arrangement is with recourse, the subsidiary retains the credit risk associated with the underlying receivables and accordingly continues to recognize the related accounts receivable on its balance sheet. Amounts advanced by the bank are recognized as current liability at fair value, which approximates the actual proceeds received due to the short-term nature of the advances, generally ranging from 60 to 120 days. Interest incurred on the advances is recognized as finance expense in the period incurred. Since the arrangement does not constitute a transfer of receivables under applicable accounting standards, no gain or loss is recognized on the transaction. This facility incurred a factoring interest rate ranging from 4.1% to 4.7% during nine months ended September 30, 2026, whereas the interest cost during the nine months ended September 30, 2026, amounting to $65. Cash advances received from such arrangement during the period ended September 30, 2026, were $4,772. The carrying amount of associated recourse financing liability was $3,755 as at September 30, 2026. See also note 10(D) below.

 

B. 2025 Convertible Notes

 

As of December 31, 2025, the 2025 Convertible Notes had a fair value of $10,543. During the period ended September 30, 2026, the Company repaid $3,340, converted $10,167 of the notes to common stock, and recognized a charge of $2,964 arising from changes in fair value.

 

On June 12, 2026, the Company used a portion of the proceeds from the issuance of the 2026 Convertible Notes (see note 10[C]) to settle the remaining obligations under the 2025 Convertible Notes. The remaining liability was remeasured to fair value immediately prior to settlement, and derecognized upon payment of the settlement consideration.

 

As a result of the repayments, conversions and changes in fair value during the nine months ended September 30, 2026, the Company had no outstanding obligations under the 2025 Convertible Notes as of September 30, 2026.

 

18

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

The following table represents changes in the fair value of the 2025 Debentures for the periods presented:

 

    September 30,
2026
    December 31,
2025
 
Opening balance - fair value   $ 10,543     $ 12,000  
Less: Debt repayment     (3,340 )     -  
Less: Conversions to equity stock (fair value)     (10,167 )     (1,416 )
Changes in fair value (recognized in earnings)     2,964       (41 )
Closing balance - fair value   $ -     $ 10,543  

 

C. 2026 Convertible Notes

 

On June 12, 2026, the Company completed a private placement to unrelated institutional investors of 15% original issue discount senior convertible promissory notes (“2026 Debentures”) with an aggregate principal amount of approximately $4,235 for aggregate gross cash proceeds of $3,600(1). The difference between the aggregate face value of $4,235 and the proceeds of $3,600 represents an original issue discount of $635, which is reflected in the initial fair value measurement of the debentures. The notes mature on December 12, 2026. The 2026 Debentures are convertible into shares of the Company’s common stock at the holders’ option after the applicable contractual conversion date at a conversion price equal to 85% of the volume-weighted average price of the Company’s common stock for the three trading days immediately preceding conversion, subject to a floor price of $0.452 per share ($9.04 per share adjusted for the effect of reverse stock-split of one-for-twenty effective October 26, 2026) and certain adjustments.

 

The Company has the option to prepay the 2026 Debentures at 102.5% of the principal amount being prepaid plus accrued interest and other amounts owing. In addition, the Company is generally required to apply 25% of the net proceeds from specified subsequent financing transactions toward repayment of the notes unless waived by the applicable holder. The 2026 Debentures bear interest at 10% per annum upon the occurrence and continuation of an event of default. The Company may extend the maturity date for three months, in which case the outstanding principal amount is increased by 10%.

 

The Company elected the fair value option for these debentures under ASC 825, Financial Instruments, at initial recognition. Accordingly, the 2026 Debentures are recorded at fair value and remeasured at each reporting date, with changes in fair value recognized in earnings.

 

The fair value of these debentures is classified within Level 3 of the fair value hierarchy because the valuation uses significant unobservable inputs and management judgment. The Company engaged an independent third-party valuation specialist to estimate the fair value of the debentures using a Monte Carlo simulation model. The valuation model simulated multiple potential future stock-price paths and expected settlement outcomes and incorporated the contractual terms of the instruments, including the variable conversion feature, floor price, maturity, and other debt-specific provisions.

 

The following table represents changes in the fair value of the 2026 Debentures for the periods presented:

 

    September 30,
2026
    December 31,
2025
 
Fair value at issuance   $ 3,600     $              -  
Changes in fair value (recognized in earnings)     752       -  
Repayments during the period(2)     (750 )        
Closing balance - fair value   $ 3,602     $ -  

 

(1)

In connection with the issuance of the 2026 Debentures, the Company incurred expenses amounting to $481, which were recognized in the condensed consolidated statement of operations and comprehensive loss for the period ended September 30, 2026.
(2) The repayments represent 25% of the net proceeds raised from specified financing activities carried out by the Company under ELOC and At-The-Market placements, in accordance with the terms of the 2026 Debentures. Accordingly, $750 was repaid during the period ended September 30, 2026, whereas $330 was repaid on October 1, 2026.

 

As of September 30, 2026, significant assumptions used by an independent third-party valuer in the valuation included the Company’s common stock price of $0.72 per share (pre reverse stock-split effective October 26, 2026), expected volatility range of 79.2% - 103.3%, a risk-free rate of 4.16%, and a remaining contractual term of approximately 0.2 years. The valuation also reflected assumptions regarding expected conversion behavior and settlement outcomes over the remaining life of the instruments. In addition, the model was calibrated to observed transaction proceeds. No financing below the contractual floor price is expected in 2026, and accordingly no floor-reset event was incorporated into the September 30, 2026, valuation.

 

19

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

D. Debt from credit institutions

 

Teyame and Datono have secured various credit facilities across multiple financial institutions. As of September 30, 2026, the total available credit facilities and loans amounted to $8,342, and the amount withdrawn and utilized as of that date was $7,782, of which $5,142 is due within a period of 12 months from the balance sheet date, whereas $2,640 is classified as long-term debt with maturity dates falling due beyond 1 year. These loans and facilities carry interest rates ranging from 1.1% - 5.83% and are obtained to cover the working capital and liquidity needs.

 

                    As of     Drawdown     Repayments           As of              
    Facility   Interest       Maturity   January 1,     during     during     Less:     September 30,     Short     Long  
Credit institution   type   rate   Conditions   date   2026     the period     the period     CTA     2026     term     term  
Ibercaja multiproducto   Working capital   4.60%   Eur 6m + 1.25%   03-15-2027     22       -       22       -               -       -       -  
Caixabank   "   1.30%   Fixed   10-26-2026     (1 )     4,674       4,504       4       165       165       -  
Bankinter   "   5.83%   Eur 12m + 2.50%   02-10-2027     -       333       333       -       -       -       -  
Bankinter Línea Pago Impuestos   "   1,1% trim.   One-time fee of 1.1% for 3 months   02-10-2027     -       -       -       -       -       -       -  
Bsantander   "       Eur 6m + 2.25%   05-13-2026     -       7,862       7,862       -       -       -       -  
BBVA   "   4.31%   Eur 3m + 1.40%   10-05-2027     (1 )     9,318       9,033       7       277       -       277  
BBVA Click & Pay   "   4.85%   Eur 6m + 1.5%   06-21-2027     257       318       282       9       284       284       -  
Caixabank   "   4.83%   Eur 12m + 1.50%   11-27-2026     (4 )     18,432       18,314       3       111       111       -  
Abanca   "   1.80%   Fixed   07-05-2027     226       2,100       2,093       8       225       225       -  
Unicaja   "   4.51%   Eur 3m + 1.40%   06-23-2027     1       1,953       1,722       6       226       226       -  
Ibercaja Multiproducto Multiempresa   "   4.60%   Eur 6m + 1.25%   03-15-2027     452       1,116       1,099       15       454       454       -  
Targobank   "   1.51%   Fixed   05-29-2026     39       -       39       -       -       -       -  
Deutsche   "   4.83%   Eur 12m + 1.50%   09-05-2027     -       8,756       8,583       4       169       169       -  
Bankia   Term loan   1.50%   Fixed   04-27-2026     20       -       20       -       -       -       -  
Bsabadell   "   5.40%   Eur 12m + 1.10%   04-29-2028     244       -       76       6       162       101       61  
BBVA   "   4.00%   Fixed   06-03-2031     (4 )      581       23       13       541       104       437  
Bankinter   Working capital   4.16%   Eur 3m + 1.25%   02-10-2027     185       358       452       4       87       87       -  
Caixabank   "   4.11%   Eur 3m + 1.20%   10-22-2026     821       2,458       2,458       27       794       794       -  
Deutsche   "   4.65%   Eur 6m + 1.50%   07-04-2029     1,291       3,062       2,946       46       1,361       -       1,361  
Ibercaja Multiproducto Multiempresa   "   4.20%   Eur 3m + 1.25%   03-15-2027     64       220       189       3       92       92       -  
Abanca   "   4.76%   Eur 3m + 1.85%   05-20-2027     234       868       811       9       282       282       -  
Caixabank   "   1.30%   Fixed   10-26-2026     -       9,999       9,768       6       225       225       -  
Bankinter   "   5.83%   Eur 12m + 2.50%   02-10-2027     -       380       380       -       -       -       -  
Bankinter Línea Pago Impuestos   "   1,1% trim.   One-time fee of 1.1% for 3 months   02-10-2027     117       -       116       1       -       -       -  
Bsantander   "       Eur 6m + 1.86%   05-11-2026     -       2,832       2,832       -       -       -       -  
BBVA   "   4.31%   Eur 3m + 1.40%   10-05-2027     (2 )     7,599       7,312       7       278       -       278  
BBVA Click & Pay   "   4.85%   Eur 6m + 1.5%   06-21-2027     294       444       453       10       275       275       -  
Caixabank   "   4.83%   Eur 12m + 1.50%   11-27-2026     (2 )     11,333       11,328       -       3       3       -  
Ibercaja   "   4.16%   Eur 3m + 1.25%   03-15-2027     126       2,766       2,717       5       170       170       -  
Deutsche   "   4.83%   Eur 12m + 1.50%   09-05-2027     -       6,052       5,936       3       113       113       -  
BBVA   Term loan   4.60%   Eur 12m + 2.50%   04-27-2026     32       -       32       -       -       -       -  
Deutsche   "   4.38%   Eur 12m + 1.65%   11-23-2026     82       -       66       1       15       15       -  
Caixabank   Working capital   4.11%   Eur 3m + 1.20%   10-22-2026     1,290       3,835       3,835       43       1,247       1,247       -  
Deutsche   "   4.55%   Eur 6m + 1.50%   07-04-2029     234       1,046       1,046       8       226       -       226  
                      6,017       108,695       106,682       248       7,782       5,142       2,640  

 

20

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

Fiscal Year   As of
September 30,
2026
    As of December 31,
2025
 
Next 12 months   $ 5,142     $            -  
12-24 months     714       -  
24-36 months     1,688       -  
Above 36 months     238       -  
Total   $ 7,782     $ -  

 

    September 30,
2026
    December 31,
2025
 
Current   $ 5,142     $               -  
Non-current     2,640       -  
Total   $ 7,782     $ -  

 

The debt with credit institutions was acquired as part of the Teyame and Datono business combination on January 1, 2026, and represents liabilities assumed at the acquisition date. See also note 6(B).

 

11) Other current liability

 

Particulars   September 30,
2026
    December 31,
2025
 
Purchase consideration payable (refer note 6[B])   $ 1,400     $            -  
Professional fees payable     619       -  
Unearned revenue     349       97  
Commission accrual     406       411  
Accrued payroll     281       216  
Director’s fees     -       55  
Insurance     -       179  
Others     351       353 *
Total   $ 3,406     $ 1,311  

 

* Corresponding figures have been rearranged for the purposes of comparison.

 

12) Contingent consideration

 

On January 22, 2026, Healthcare Triangle, Inc. entered into a share purchase agreement to acquire Teyame 360 S.L. (“Teyame”) and Datono Mediacion S.L. (“Datono”) through its wholly owned subsidiary Teyame AI Holdings Inc., effective January 1, 2026. The aggregate purchase price for the Acquired Companies is up to $50,000, subject to the terms and conditions set forth in the Share Purchase Agreement. The consideration consists of a cash component and equity component, with an additional earnout component payable in the Company’s preferred stock upon achievement of specified post-closing performance targets. The Share Purchase Agreement also provides for an earnout payable in the Company’s preferred stock to the previous owners of the Acquired Companies, with an aggregate value of up to $5,000, subject to achievement of specified annual targets as outlined in the Share Purchase Agreement. See note 6(B) for details.

 

21

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

13) Stockholders’ Equity

 

All references to the number of common shares and price per Common Stock, for all periods presented, have been adjusted to reflect the following:

 

  - one-for-sixty reverse stock-split effective February 10, 2026, and
     
  - one-for-twenty reverse stock-split effective October 26, 2026, (see note 18).

 

These reverse splits reduced the number of issued and outstanding shares of common stock in proportion to the split ratio, without changing the total authorized shares or the par value per share. Basic and diluted net loss per share reflect the effect of the reverse stock-splits for all periods presented.

 

Accordingly, unless indicated otherwise, all the current period and historical per share data, number of shares issued and outstanding, stock awards, and other common stock equivalents for the periods presented in this Report on Form 10-Q have been adjusted retroactively, where applicable, to reflect the reverse stock-split.

 

The reverse stock-split affected all common stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity. The Company issued fractional shares at the participant level in connection with the reverse stock-split. The reverse stock-split did not impact holders of Preferred equity, or the portion of stocks allocated for employee stock options.

 

A. Common Stock

 

i. Equity Issuance and Pre-Funded Warrants for Business Combination

 

On January 22, 2026, Healthcare Triangle, Inc. entered into a share purchase agreement to acquire Teyame 360 S.L. (“Teyame”) and Datono Mediacion S.L. (“Datono”) through its wholly owned subsidiary Teyame AI Holdings Inc. The aggregate purchase price for the Acquired Companies is up to $50,000, subject to the terms and conditions set forth in the Share Purchase Agreement.

 

The consideration consists of a cash payout of $15,000 together with equity component, split between common stock amounting to $12,000 and preferred stock amounting to $18,000 convertible into common stock upon Company’s stockholders’ approval, with an additional earnout component payable in the Company’s preferred stock upon achievement of specified post-closing performance targets.

 

The number of shares of common stock issued as part of the equity consideration, and the number of shares of common stock underlying the preferred stock, were determined by reference to a “Base Price” equal to the average of the volume-weighted average prices (“VWAPs”) of the Company’s common stock for the five trading days immediately prior to the Closing Date, as further defined in the Share Purchase Agreement. The preferred stocks were converted into common stock subsequent to the stockholder approval on July 17, 2026, as contemplated by the Share Purchase Agreement.

 

During the period ended September 30, 2026, a total of 488,703 shares of common equity (9,774,055 shares prior to the reverse stock-split of 1:20 effected on October 26, 2026), were issued towards the full settlement of equity components of the purchase consideration of $12,000 and $18,000 respectively. Of these, 2,784 shares (55,682 shares prior to the reverse stock-split of 1:20 effected on October 26, 2026) were issued prior to June 30, 2026, whereas the remaining shares were issued during the quarter ended September 30, 2026. See note 6(B) for further details.

 

ii. Pre-Funded Warrants

 

●

On February 26, 2026, the Company completed a registered direct offering pursuant to which it issued and sold an aggregate of 681,553 securities (34,078 subsequent to reverse stock-split of 1:20 effective October 26, 2026) at a purchase price of $5.81 per security ($116.20 subsequent to reverse stock-split of 1:20 effective October 26, 2026), consisting of 421,553 shares (21,078 shares subsequent to the reverse stock-split on October 26, 2026) of common stock and 260,000 pre-funded warrants (13,000 warrants subsequent to the reverse stock-split effective October 26, 2026) to purchase shares of common stock, which were exercised immediately upon issuance. The pre-funded warrants were issued in lieu of shares of common stock to certain investors whose purchase of common stock would otherwise have resulted in such investors exceeding applicable beneficial ownership limitations. Each pre-funded warrant had an exercise price of $0.00001 per share, was immediately exercisable, and remained exercisable until exercised in full, subject to the beneficial ownership limitations set forth in the warrant agreement. All warrants were exercised in full during the period ended September 30, 2026. See below (D) for details.

 

The Company received net proceeds of approximately $3,563 after deducting commissions and other offering expenses of approximately $397. Consistent with U.S. GAAP, the Company recorded the net amount within additional paid-in capital on the accompanying consolidated balance sheet as the securities met all the criteria for equity classification.

 

● In connection with the Equity Purchase Agreement (“ELOC”, see point [D] below), on June 12, 2026, the Company issued Hudson a five-year common stock purchase warrant (“ELOC warrant”) to purchase 50,000 shares of common stock (2,500 shares subsequent to the reverse stock-split on October 26, 2026) at an exercise price of $0.00001 per share. The warrant, exercisable on a cash or cashless basis, was fully earned upon issuance. During the period ended September 30, 2026, shares totaling 50,000 (2,500 shares subsequent to the one-for-twenty reverse stock-split on October 26, 2026) were issued to Hudson. The warrant was issued as a commitment fee for Hudson Global’s agreement to enter into the ELOC. The Company determined that the warrant qualifies for equity classification. Accordingly, the grant-date fair value of the warrant of $112 has been recognized in other current assets as deferred ELOC offering cost and is being amortized against future ELOC financings to additional paid-in capital, as and when the transactions occur. During the period ended September 30, 2026, $2 was amortized accordingly.

 

22

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

The movement of warrants during the periods ended September 30, 2026, and 2025, is shown below:

 

          Weighted     Average  
          Average     Remaining  
    Number of     Exercise     Contractual  
Warrants   Warrants     price     Term  
Outstanding on January 1, 2026     1,238     $ 10,181       4.17  
Granted during the period(*):                        
Registered direct offering (see note above)     13,000       41.11       -  
Pre-funded warrants (Teyame, see note 6[B])     21,243       -       -  
ELOC warrant (see note above)     2,500       -       -  
Exercised during the period(*)     (36,743 )     14.55       -  
Outstanding on September 30, 2026     1,238       10,181       3.41  
Exercisable on September 30, 2026     1,238     $ 10,181       3.41  

 

(*) Warrants granted during the period ended September 30, 2026, were fully exercised during the same period.

 

                Weighted  
          Weighted     Average  
          Average     Remaining  
    Number of     Exercise     Contractual  
Warrants   Warrants     price     Term  
Outstanding on January 1, 2025     3     $ 2,388,592       3.05  
Issued during the period(*)     1,211       3,954       4.42  
Outstanding on September 30, 2025(*)     1,214       9,847       2.30  
Exercisable on September 30, 2025(*)     1,214     $ 9,847       2.30  

 

(*) Comparatives have been rearranged for the purposes of comparison.

 

B. Preferred Series ‘B’ stock

 

On July 28, 2026, following stockholder approval, the Company completed the exchange and cancellation of all 1,600,000 outstanding shares of its Series ‘B’ Convertible Preferred Stock held by SecureKloud Technologies Limited (“SecureKloud”), a related party. Pursuant to the Securities Exchange Agreement dated June 24, 2026, the Series ‘B’ Preferred Stock was surrendered to the Company and cancelled, and the Company issued 2,828,167 shares (141,408 shares subsequent to the one-for-twenty reverse stock-split effective October 26, 2026) of common stock to SecureKloud’s designated nominees. Upon cancellation, the Series ‘B’ Preferred Stock returned to the status of authorized, but unissued, preferred stock.

 

Immediately prior to the exchange, the Series ‘B’ Preferred Stock had a carrying amount of approximately $7,435. The Company accounted for the transaction as an extinguishment of preferred stock. The common shares issued were measured at an estimated fair value of approximately $3,282 as of July 22, 2026. Fair value was determined based on the Company’s quoted Nasdaq closing price of $1.63 per share, adjusted for the legal resale restrictions applicable to the unregistered shares using a Black-Scholes protective-put methodology. The resulting discount for lack of marketability was approximately 28.8%.

 

In evaluating the qualitative nature and integrated terms of the settlement, the Company determined that the $626 advance due from SecureKloud constituted additional consideration in the preferred-stock exchange rather than a separate operating settlement. Accordingly, during the three months ended September 30, 2026, the Company reversed the previously recognized settlement provision through earnings and reflected the settlement of the advance directly within stockholders’ equity. The adjustment was noncash and had no effect on total stockholders’ equity as of September 30, 2026. See also note 5.

 

Total consideration transferred, including the common shares issued and settlement of the advance, was approximately $3,908. The difference of $3,527 between the carrying amount of the Series B Preferred Stock and the total consideration transferred was recognized within stockholders’ equity as a deemed contribution from the preferred stockholder. No gain or loss from the preferred-stock extinguishment was recognized in the condensed consolidated statements of operations.

 

For earnings-per-share purposes, the deemed contribution was added to net income (loss) in determining income (loss) available to common stockholders. The common shares issued in the exchange were included in weighted-average common shares outstanding from July 28, 2026, giving retrospective effect to the subsequent reverse stock split.

 

C. Conversion of Debt to Equity

 

During the period ended September 30, 2026, the holders of the 2025 Debentures converted a portion of the Debentures into 27,086,245 shares of common stock (22,572 shares post reverse stock-splits of one-for-sixty and one-for-twenty, effective February 2026, and October 26, 2026, respectively). See note 10(B) for details.

23

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

D. Equity Financing

 

During the period ended September 30, 2026, the Company completed several equity financing activities designed to strengthen liquidity, support working capital needs, and fund general corporate and strategic initiatives.

 

i. On February 26, 2026, the Company entered into a securities purchase agreement in connection with a registered direct offering, pursuant to which the Company agreed to sell an aggregate of 681,553 securities at a purchase price of $5.81 per security, for aggregate gross proceeds of approximately $3,960, before placement agent fees of 7% and other offering expenses. The offering consisted of 421,553 shares (21,078 shares subsequent to the one-for-twenty reverse stock-split effective October 26, 2026) of the Company’s common stock and 260,000 pre-funded warrants (13,000 warrants subsequent to the one-for-twenty reverse stock-split effective October 26, 2026) to purchase shares of common stock.

 

The pre-funded warrants were deemed cashless and were issued in lieu of common stock to certain investors and exercisable immediately for an aggregate of 260,000 shares (13,000 shares post reverse stock-split of one-for-twenty effective October 26, 2026) of common stock, subject to customary anti-dilution adjustments. The warrants were exercised in full during the period ended September 30, 2026 (see note 13[A(ii)] above). The pre-funded warrants also provide for cashless exercise in certain circumstances, including if an effective registration statement or current prospectus is not available for the issuance of the underlying shares.

 

The Company received net proceeds of approximately $3,563 after deducting commissions and other offering expenses of approximately $397. Consistent with U.S. GAAP, the commissions and offering costs are recorded as a reduction of additional paid-in capital within stockholders’ equity.

 

ii. At-The-Market Placements

 

During the period ended September 30, 2026, the Company issued shares of its common stock pursuant to its At-the-Market Sales Agreement dated November 18, 2025. The Company sold an aggregate of 3,452,307 shares (172,615 shares subsequent to the one-for-twenty reverse stock-split effective October 26, 2026) of its common stock at the prevailing market prices, generating gross proceeds of approximately $10,135. In addition, pursuant to the Company’s approved share buy-back program, 127,248 shares (6,362 shares subsequent to the one-for-twenty reverse stock-split effective October 26, 2026) were bought-back by the Company at prevailing market prices at a gross amount of $98. In accordance with the terms of the Sales Agreement, the Company paid commission totaling 3% of the gross proceeds from each sale or purchase, in addition to other customary offering expenses. Total commissions and offering-related costs of approximately $322 were incurred in connection with these issuances. The Company received net proceeds of approximately $9,633 after deducting commissions and other offering expenses, whereas $82 are receivable as of September 30, 2026. Consistent with U.S. GAAP, the net proceeds are recorded in the additional paid-in capital within stockholders’ equity.

 

  iii. Equity line of credit (ELOC)

 

On June 12, 2026, the Company entered into an Equity Purchase Agreement and a Registration Rights Agreement with Hudson Global Ventures, LLC (“Hudson”). Under the Equity Purchase Agreement, the Company has the right, but not the obligation, to sell to Hudson, from time to time and at the Company’s sole discretion, shares of the Company’s common stock for aggregate gross proceeds of up to $50,000 during a commitment period of up to 36 months, subject to earlier termination and the satisfaction of the conditions contained in the agreement.

 

On July 17, 2026, the Company’s stockholders approved the issuance of common stock in excess of the Nasdaq exchange cap under the Equity Purchase Agreement, in accordance with Nasdaq Listing Rule 5635(d).

 

On September 22, 2026, the Company amended the Equity Purchase Agreement to reduce the maximum amount per purchase notice from $2,500 to $250, subject to a further limit of 200% of the Company’s average daily trading value. The amendment also revised the purchase price to 94% of the average of the three lowest traded prices during the five trading days preceding the purchase notice and increased the minimum trading-price requirement from $0.01 to $0.10 per share, before adjustment for the October 2026 reverse stock split.

 

The Company’s ability to sell shares under the agreement remains subject to an effective resale registration statement, continued Nasdaq listing, minimum trading-price requirements and other customary conditions. Hudson may not purchase shares to the extent that its beneficial ownership would exceed 4.99% of the Company’s outstanding common stock.

 

In connection with the agreement, the Company issued Hudson a five-year warrant to purchase 50,000 shares of common stock (2,500 shares subsequent to the one-for-twenty reverse stock-split on October 26, 2026) at an exercise price of $0.00001 per share. The warrant was fully earned upon issuance and qualified for equity classification. Its grant-date fair value of $112 was recorded as a deferred offering cost within other current assets, with a corresponding increase in additional paid-in capital. On July 22, 2026, Hudson exercised the warrant in full on a cashless basis. During the nine months ended September 30, 2026, the Company charged $2 of deferred offering costs against the proceeds of ELOC share issuances as a reduction of additional paid-in capital.

 

During the nine months ended September 30, 2026, the Company completed two draws under the Equity Purchase Agreement, issuing 350,000 shares of common stock (17,500 shares after the October 26, 2026 reverse stock split). The Company received gross proceeds of $338 and incurred offering costs of $25, resulting in net cash proceeds of $313. The share issuances were recorded within stockholders’ equity, net of the related offering costs.

 

As of September 30, 2026, the remaining maximum contractual commitment under the Equity Purchase Agreement was approximately $49,662. The Company’s ability to raise additional capital under the agreement remains subject to market conditions and the satisfaction of the applicable contractual requirements.

24

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

14) Segment Information

 

Schedule of operating segments 

 

    Three months ended
September 30,
    Changes  
    2026     2025     Amount     %  
Software services   $ 1,202     $ 2,040     $ (838 )     (41 )%
Managed services and support     1,316       1,379       (63 )     (5 )%
Customer engagement services (*)     6,525       -       6,525       100 %
All others     73       70       3       4 %
Revenue   $ 9,116     $ 3,489     $ 5,627       161 %

 

(*) represents segment acquired as part of business combination. See note 6(B) for details.

 

    Nine months ended
September 30,
    Changes  
    2026     2025     Amount     %  
Software services   $ 4,302     $ 6,305     $ (2,003 )     (32 )%
Managed services and support     3,939       4,235       (296 )     (7 )%
Customer engagement services (*)     19,709       -       19,709       100 %
All others     212       212       -       - %
Revenue   $ 28,162     $ 10,752     $ 17,410       162 %

 

(*) represents segment acquired as part of business combination. See note 6(B) for details.

 

Operating Results by Operating Segment

 

During the three months ended September 30, 2026, the Company refined and simplified the presentation of its segment disclosures in accordance with ASC 280, Segment Reporting, to better align with the financial information regularly provided to its Chief Operating Decision Makers (“CODMs”) for evaluating operating performance and allocating resources.

 

The revised presentation focuses on reportable segment revenues, the measure of segment profit or loss used by the CODMs and other disclosures required under ASC 280. Amounts previously presented under “Corporate and Others” have been reclassified, as applicable, to “All others” non-reportable business activities or unallocated corporate reconciling items, as corporate activities do not constitute a reportable operating segment.

 

25

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

Comparative segment information for the three and nine months ended September 30, 2025, has been reclassified to conform to the current-period presentation. These changes have no impact on the Company’s previously reported consolidated financial position, results of operations or cash flows.

 

Three months ended September 30, 2026
    Software     Managed     Customer
Engagement
    All     Total
Reportable
    Corporate
and other
    Consolidated  
    Services     Services     Services*     others     Segments     items     Total  
Revenue   $ 1,202       1,316       6,525       73       9,116       -       9,116  
Cost of revenue     (1,041 )     (1,009 )     (4,706 )     (279 )     (7,035 )     -       (7,035 )
Sales and marketing     (117 )     (114 )     (444 )     -       (675 )     (863 )     (1,538 )
General and administrative     (186 )     (46 )     (1,259 )     -       (1,491 )     (722 )     (2,213 )
Others, net     (45 )     -       30       -       (15 )     (861 )     (876 )
Profit / (loss) before income taxes   $ (187 )     147       146       (206 )     (100 )     (2,446 )     (2,546 )

 

(*) represents segment acquired as part of business combination. See note 6(B) for details.

 

Nine months ended September 30, 2026
    Software
Services
    Managed
Services
    Customer
Engagement
Services*
    All
others
    Total
Reportable  
Segments
    Corporate
and other
items
    Consolidated
Total
 
Revenue   $ 4,302       3,939       19,709       212       28,162       -       28,162  
Cost of revenue     (3,637 )     (3,060 )     (14,221 )     (704 )     (21,622 )     -       (21,622 )
Sales and marketing     (343 )     (281 )     (519 )     -       (1,143 )     (2,895 )     (4,038 )
General and administrative     (936 )     (373 )     (4,447 )     -       (5,756 )     (4,495 )     (10,251 )
Others, net     (63 )     -       (500 )     -       (563 )     (4,824 )     (5,387 )
Profit / (loss) before income taxes   $ (677 )     225       22       (492 )     (922 )     (12,214 )     (13,136 )

 

(*) represents segment acquired as part of business combination. See note 6(B) for details.

 

Three months ended September 30, 20251
    Software
Services
    Managed
Services
    All
others
    Total
Reportable  
Segments
    Corporate
and other
items
    Consolidated
Total
 
Revenue   $ 2,040       1,379       70       3,489       -       3,489  
Cost of revenue     (1,738 )     (1,092 )     (41 )     (2,871 )     -       (2,871 )
Sales and marketing     (280 )     (173 )     -       (453 )     (569 )     (1,022 )
General and administrative     (652 )     (299 )     -       (951 )     (1,134 )     (2,085 )
Others, net     -       -       -       -       583       583  
Profit / (loss) before income taxes   $ (630 )     (185 )     29       (786 )     (1,120 )     (1,906 )

 

(1) Comparatives have been rearranged for the purposes of comparison.

 

26

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

Nine months ended September 30, 20251
    Software
Services
    Managed
Services
    Others     Total
Reportable  
Segments
    Corporate
and other
items
    Consolidated
Total
 
Revenue   $ 6,305       4,235       212       10,752       -       10,752  
Cost of revenue     (5,588 )     (3,548 )     (174 )     (9,310 )     -       (9,310 )
Sales and marketing     (618 )     (398 )     -       (1,016 )     (996 )     (2,012 )
General and administrative     (832 )     (419 )     -       (1,251 )     (3,213 )     (4,464 )
Others, net     -       -       -       -       61       61  
Profit / (loss) before income taxes   $ (733 )     (130 )     38       (825 )     (4,148 )     (4,973 )

 

(1) Comparatives have been rearranged for the purposes of comparison.

 

Revenue from top 5 customers

 

Schedule of concentration

 

    Three months ended
September 30, 2026
    Nine months ended
September 30, 2026
 
Customer   Amount     % of
Revenue
    Amount     % of
Revenue
 
Customer 1   $ 2,647       29 %   $ 7,794       28 %
Customer 2     745       8 %     2,258       8 %
Customer 3     688       8 %     2,013       7 %
Customer 4     663       7 %     1,978       7 %
Customer 5   $ 588       6 %   $ 1,812       6 %

 

(*) represents customer acquired as part of business combination. See note 6(B) for details.

  

    Three months ended
September 30, 2025
    Nine months ended
September 30, 2025
 
Customer   Amount     % of
Revenue
    Amount     % of
Revenue
 
Customer 1   $ 689       20 %   $ 2,039       19 %
Customer 2     583       17 %     2,017       19 %
Customer 3     296       8 %     899       8 %
Customer 4     235       7 %     664       6 %
Customer 5   $ 133       4 %   $ 447       4 %

 

(*) represents customer acquired as part of business combination. See note 6(B) for details.

 

27

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

15) Legal Matters

 

On 13 August 2026, L1 Capital Global Opportunities Master Fund Ltd filed proceedings against the Company in the Grand Court of the Cayman Islands (FSD 257 of 2026). It seeks declarations that the exercise price of, and the number of shares issuable under, its warrant dated 28 December 2023 have been adjusted. The proceedings were served on the Company on 19 October 2026 and are at an early stage, and no hearing of the claim has taken place. The Company has instructed Cayman Islands counsel and is taking legal advice.

 

All legal costs are expensed as incurred.

 

16) Stock Based Compensation

 

    September 30,
2026
    December 31,
2025
 
Opening share options outstanding     135       2  
Vested / granted during the period / year     -       133  
Forfeited / expired     -       -  
Closing share options outstanding     135       135  

 

Schedule of stock option activity

 

The employee options balance available under the plan (for issuance) were 3,999,865 as of September 30, 2026, and December 31, 2025. The employee stock option balance available under the plan was not impacted by the reverse stock-split of 1:20 effective October 26, 2026.

 

There were no unvested options outstanding as of September 30, 2026.

 

The following table summarizes the activities for our unvested options for the period ended September 30, 2025.

 

    Number of     Weighted
average
Grant Date
Fair Value
 
    Shares     Per Share  
Unvested on January 1, 2025       -     -  
Granted     133       3,144  
Vested     (133 )     3,144  
Unvested on September 30, 2025     -       - 

 

17) Income / (loss) per share

 

    Three months ended  
    September 30,  
    2026     2025  
Net profit / (loss) attributable to common stockholders   $ 1,054 (*)   $ (1,888 )
Weighted average shares outstanding used in basic EPS computations     620,496       3,703  
Weighted average shares outstanding used in diluted EPS computations     872,744       -  
Basic EPS – Stockholders   $ 1.70     $ (509.53 )
Diluted EPS – Stockholders   $ 1.21     $ (509.53 )

 

(*) For earnings-per-share calculation and presentation purposes, the deemed contribution was added to net income (loss) in determining income (loss) available to common stockholders - (see note 13[B]).

 

28

 

 

HEALTHCARE TRIANGLE, INC.

Notes To Condensed Consolidated Financial Statements

(Unaudited)

(In thousands except share and per share data)

 

    Nine months ended  
    September 30,  
    2026     2025  
Net loss attributable to common stockholders   $ (9,509 )(1)   $ (4,955 )
Weighted average shares outstanding used in basic per common share computations     258,212       1,846  
Basic / Diluted EPS – Stockholders(*)   $ (36.83 )   $ (2,683.58 )

 

(*) Due to net loss position, basic and diluted weighted average shares outstanding are the same.

 

(1) For earnings-per-share calculation and presentation purposes, the deemed contribution was added to net income (loss) in determining income (loss) available to common stockholders (see note 13[B]).

 

18) Subsequent Events

 

i. The Company effected a one-for-twenty reverse stock-split of its issued and outstanding common stock on October 26, 2026. The reverse split reduced the number of issued and outstanding shares of common stock in proportion to the split ratio, without changing the total authorized shares or the par value per share. Basic and diluted net loss per share reflect the effect of the reverse stock-split for all periods presented.

 

  ii. Subsequent to September 30, 2026, the Company continued to advance its previously announced plan to separate Teyame AI Holdings Inc., a consolidated subsidiary of the Company, and pursue a direct listing of its common stock. In connection with the proposed separation, Teyame AI Holdings Inc. intends to file a registration statement on Form 10 with the Securities and Exchange Commission to register its common stock under the Securities Exchange Act of 1934. The proposed transaction is expected to include a distribution of a portion of Teyame AI Holdings Inc.’s outstanding common stock to the Company’s stockholders, with the Company retaining a controlling ownership interest in Teyame AI Holdings Inc. following the distribution. The proposed separation, distribution and direct listing remain subject to completion of the Form 10 registration process, applicable regulatory and stock exchange requirements, final corporate approvals and other customary conditions. Accordingly, there can be no assurance as to the timing or completion of the proposed transaction. 
     
  iii. Effective October 1, 2026, the Company initiated a strategic realignment of its U.S. operations through Purpose Health Inc., its wholly owned subsidiary. As part of this transition, certain U.S. customer contracts and related business development, project support and service delivery activities are being transferred to Purpose Health Inc., while certain corporate and administrative functions will continue to be managed by the Company.   The transition is being implemented through applicable intercompany agreements and customer and vendor arrangements. As Purpose Health Inc. remains a wholly owned consolidated subsidiary, the internal restructuring is not expected to have a material impact on the Company’s consolidated financial position or results of operations.
     
  iv. Subsequent to September 30, 2026, the Company issued an aggregate of 28,602 shares of common stock through its At-The-Market placement agreement, and received aggregate proceeds of approximately $144, after deducting contractual clearing and transaction costs of approximately $4. The shares were issued subsequent to September 30, 2026, and, accordingly, no amounts related to these draws were recognized in the Company’s unaudited condensed consolidated financial statements as of September 30, 2026.
     
  v. See note 15, Legal Matters, for developments after September 30, 2026, in the proceedings initiated by L1 Capital Global Opportunities Master Fund Ltd. (“L1 Capital”) against the Company.

 

  vi. On October 1, 2026, the Company received a Staff Delisting Determination from The Nasdaq Stock Market LLC (“Nasdaq”) due to noncompliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company was not eligible for a compliance period because it had effected reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one (a one-for-249 reverse stock-split on August 1, 2025, and a one-for-sixty reverse stock-split on February 10, 2026).

 

On October 8, 2026, the Company requested a hearing before the Nasdaq Hearings Panel to appeal the determination. The appeal stayed the suspension of trading and delisting proceedings pending the Panel’s decision.

 

29

 

 

HEALTHCARE TRIANGLE, INC.
Notes To Condensed Consolidated Financial Statements

(Unaudited)
(In thousands except share and per share data)

 

On October 26, 2026, the Company completed a one-for-twenty reverse stock split of its common stock as part of its efforts to regain compliance with Nasdaq’s minimum bid price requirement. As a result, every twenty outstanding common shares were consolidated into one share. The Company’s trading symbol remains “HCTI.”

 

The Company continues to pursue its appeal and engage with Nasdaq regarding its continued listing. On November 5, 2026, the Company and its advisors presented its case before the Nasdaq Hearings Panel and it is awaiting that Panel’s decision.

 

19) New Accounting Pronouncements

 

  A. Implemented

 

    In July 2025, the FASB issued ASU No. 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The amendments in this update provide a practical expedient permitting an entity to assume that conditions at the balance sheet date remain unchanged over the life of the asset when estimating expected credit losses for current classified accounts receivable and contract assets. We adopted this ASU on a prospective basis effective January 1, 2026. While this ASU was adopted, we did not elect practical expedient permitted under this ASU. Therefore, the adoption has no impact on our consolidated financial statements.

 

  B. Not Yet Due

 

  i. ASU No. 2025-06. In September 2025, the FASB issued ASU No. 2025-06, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software,” which is intended to modernize internal-use software guidance by removing all references to project stages and by clarifying the thresholds entities apply to begin capitalizing costs. ASU No. 2025-06 is effective for fiscal years beginning after December 15, 2027, and interim periods within those annual reporting periods. Early adoption is permitted. The guidance can be applied on a prospective basis, a modified basis for in-process projects, or a retrospective basis. We are currently evaluating the impact of the standard on our consolidated financial statements.

 

  ii. ASU No. 2024-03. In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,” which is intended to improve disclosures about a public business entity’s expenses by requiring disaggregated disclosure, in the notes to the financial statements, of prescribed categories of expenses within relevant income statement captions. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The new standard may be applied either on a prospective or retrospective basis. We are currently evaluating the impact of the standard on our consolidated financial statement disclosures.

 

Recent accounting pronouncements adopted or pending adoption not discussed above are either not applicable or are not expected to have a material impact on our consolidated financial condition, results of operations, or cash flows.

 

30

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion summarizes the significant factors affecting the operating results, financial condition, liquidity, and cash flow of our Company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with the condensed consolidated financial statements and the related notes thereto, and the consolidated financial statements and the related notes thereto all included elsewhere in this Quarterly Report on Form 10-Q. The statements in this discussion regarding industry outlook, our expectations regarding our future performance, liquidity, and capital resources, and all other non-historical statements in this discussion are forward-looking statements and are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed below and elsewhere in this report, and in the section entitled “Note About Forward-Looking Statements” contained in this Quarterly Report on Form 10-Q, and in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”).

 

Overview

 

Healthcare Triangle, Inc. (the “Company”) is a leading healthcare information technology company focused on advancing innovative, industry-transforming solutions in the areas of cloud services, data science, professional and managed services for the Healthcare and Life Sciences industry.

 

The Company was formed on October 29, 2019, as a Nevada corporation and converted into a Delaware corporation on April 24, 2020, to provide IT and data services to the Healthcare and Life Sciences (“HCLS”) industry. The business commenced on January 1, 2020, after SecureKloud Technologies Inc. transferred its Life Sciences business to us.

 

On June 16, 2025, the Company, through its wholly owned subsidiary QuantumNexis Inc., a Delaware corporation, entered into an Asset and Stock Transfer Agreement (ATA) with Niyama Healthcare Inc., a provider of Mental Health and Hospital Information Systems technology, across India, Southeast Asia, and Europe (the “Seller”). Pursuant to the ATA, the Company purchased (i) the Transferred Assets (comprising of contracts, intellectual property and related assets), and (ii) 100% shareholder equity interest in Ezovion Solutions Private Limited, Chennai, India - a Hospital Information Systems SaaS Provider in exchange for a Purchase Price.

 

Effective January 1, 2026, the Company, through its wholly owned subsidiary Teyame AI Holdings Inc., a Delaware corporation, acquired Teyame 360 S.L. (“Teyame”) and Datono Mediacion S.L. (“Datono”) (see note 6[B] for details). Together, Teyame and Datono operate as an integrated platform providing AI-powered omnichannel customer experience, marketing, financial and insurance distribution services.

 

Teyame leverages its technology solutions to provide customer engagement services that combine artificial intelligence, telemarketing, and contact center operations to support customer acquisition, retention, and service. Its platform enables enterprises particularly in financial services, insurance, and healthcare to manage end-to-end customer interactions across multiple channels.

 

Datono complements this platform as an insurance brokerage entity, facilitating the marketing and sales of insurance products. Together, the companies form a vertically integrated model combining customer acquisition technology with distribution capabilities, particularly in regulated sectors such as insurance.

 

As of September 30, 2026, we had a total of 38 full-time employees and 24 sub-contractors, including 30 certified cloud engineers, 11 Epic Certified EHR experts, 6 MEDITECH Certified EHR experts, 11 Admin full-time and 4 Admin sub-contractors. Many of the senior management team and the members of our board of directors hold advanced degrees and some are leading experts in the field of technology, investment banking and public markets.

 

During the period ended September 30, 2026, the Company effected a 1-for-60 reverse split of its issued and outstanding common stock on February 10, 2026, and subsequent to the end of the period, the Company effected a 1-for-20 reverse split of its issued and outstanding common stock on October 26, 2026. Each reverse split reduced the number of issued and outstanding shares of common stock in proportion to the split ratio, without changing the total authorized shares or the par value per share.

 

Our approach leverages our proprietary technology platforms, extensive industry knowledge, and healthcare domain expertise to provide solutions and services that reinforce healthcare progress. Through our platform, solutions, and services, we support healthcare delivery organizations, healthcare insurance companies, pharmaceutical, and Life Sciences, biotech companies, and medical device manufacturers in their efforts to improve data management, develop analytical insights into their operations, and deliver measurable clinical, financial, and operational improvements.

 

We offer a comprehensive suite of software, solutions, platforms, and services that enables some of the world’s leading healthcare and pharma organizations to deliver personalized healthcare, precision medicine, advances in drug discovery, development and efficacy, collaborative research and development, respond to real-world evidence, and accelerate their digital transformation. We combine our expertise in the healthcare technology domain, cloud technologies, DevOps and automation, data engineering, advanced analytics, security, compliance, and governance to deliver platforms and solutions that drive improved results in the complex workflows of Life Sciences, biotech, healthcare providers, and payers. Our differentiated solutions, enabled by our intellectual property and delivered as a service, provide advanced analytics, data science applications, and data aggregation in these highly regulated environments in a more compliant, secure, and cost-effective manner to our customers.

 

31

 

 

Our deep expertise in healthcare technology allows us to reinforce our clients’ progress by accelerating their innovation. Our healthcare IT services include Electronic Health Records (EHR) and software implementation, optimization, extension to community partners, as well as application managed services, and backup and disaster recovery capabilities on public cloud. Our 24x7 managed services are used by hospitals and health systems, payers, Life Sciences, and biotech organizations in their effort to improve health outcomes and deliver deeper, more meaningful patient and consumer experiences. Through our services, our customers achieve a return on investment in their technology by delivering measurable improvements. Combined with our software and solutions, our services provide clients with an end-to-end partnership for their technology innovation.

 

Our Business Model

 

The majority of our revenue is generated by the AI powered Customer Engagement segment following the Company’s acquisition of Teyame and Datono effective January 1, 2026, followed by the revenue earned through our full time employees who provide Software Services and Managed Services and Support to our clients in the Healthcare and Life Sciences industry. Our Software Services include strategic advisory, implementation and development services, and Managed Services and Support include post implementation support and cloud hosting.

 

Key Factors of Success

 

We believe that our future growth, market adoption, success, and the long-term value creation associated with Teyame and Datono acquisition through our wholly-owned subsidiary Teyame AI Holdings Inc., will depend on several strategic, operational and technological factors. These factors represent significant opportunities that management must successfully address in order to realize the expected benefits of the acquisition and accelerate the combined company’s growth trajectory.

 

Investment in scaling the business

 

We need to continuously invest in sales, and marketing to promote our solutions to new and existing customers in various geographies, and other operational and administrative functions in systems, controls and governance to support our expected growth and our transition into a public company. We anticipate that our employee strength will increase over time because of such investments.

 

On June 16, 2025 (the “Closing date”), Healthcare Triangle, Inc. (the “Company”), through its wholly owned subsidiary QuantumNexis Inc., a Delaware corporation, entered into an Asset and Stock Transfer Agreement (the “Agreement”) with Niyama Healthcare, Inc., a provider of Mental Health and Hospital Information Systems technology, across India, Southeast Asia, and Europe (the “Seller”). Pursuant to the Agreement, the Company agreed to purchase from the Seller (i) the Transferred Assets (comprising of contracts, intellectual property and related assets), and (ii) the Seller’s 100% shareholder equity interest in Ezovion Solutions Private Limited, Chennai, India - Hospital Information Systems SaaS Provider as Seller’s Equity (the “Transferred Equity”), as a whole and as a going concern in exchange for the Purchase Price (as defined below). 

 

The total fair value of consideration transferred on the Acquisition Date was approximately $6,095, consisting of the following:

 

  ● Cash paid at closing and within 120 days after closing: $1,494
     
  ● Fair value of equity consideration: $4,601
     
  ● Fair value of contingent consideration (earn-out): $0

 

The deferred cash payment was discounted to present value using a market-based discount rate. The earn-out has been provisionally valued at nil based on initial probability-weighted revenue forecasts.

  

On January 22, 2026, Healthcare Triangle, Inc. entered into a share purchase agreement to acquire Teyame 360 S.L. (“Teyame”) and Datono Mediacion S.L. (“Datono”) through its wholly owned subsidiary Teyame AI Holdings Inc., effective January 1, 2026. The aggregate purchase price for the Acquired Companies is up to $50,000, subject to the terms and conditions set forth in the Share Purchase Agreement. The consideration consists of a cash payout of $15,000, with the balance settled through issuance of a combination of the Company’s common stock, preferred stock, with an additional earnout component payable in the Company’s preferred stock upon achievement of specified post-closing performance targets. 

 

The cash consideration includes: (i) $3,000 paid during 2025 pursuant to an advance agreement dated December 3, 2025, (ii) $6,000 paid during January 2026, (iii) $3,200 paid during April 2026, (iv)$1,400 paid during September 2026, and (v) $1,400 payable on the earlier of the conditions being met as outlined in the Share Purchase Agreement, or nine months from the date of the Share Purchase Agreement (but in no event prior to April 29, 2026).

 

32

 

 

The equity consideration includes: (a) restricted shares or pre-funded warrants of the Company’s common stock with an agreed value of $12,000, and (b) a series of the Company’s preferred stock with an agreed value of $18,000 that is convertible into the Company’s common stock, subject to stockholders’ approval. During the period ended September 30, 2026, a total of 488,703 shares of common equity (9,774,055 shares prior to the reverse split of 1:20 effected on October 26, 2026), were issued towards the full settlement of the equity component of purchase consideration of $12,000 and $18,000 respectively.

 

The number of shares of common stock issued as part of the equity consideration, and the number of shares of common stock underlying the preferred stock, were determined by reference to a “Base Price” equal to the average of the volume-weighted average prices (“VWAPs”) of the Company’s common stock for the five trading days immediately prior to the Closing Date, as further defined in the Share Purchase Agreement. The preferred stocks were converted into common stock subsequent to the stockholder approval on July 17, 2026 as contemplated by the Share Purchase Agreement.

 

The Share Purchase Agreement also provides for an earnout payable in the Company’s preferred stock to certain key management employees of the Acquired Companies, with an aggregate value of up to $5,000, subject to achievement of specified annual targets as outlined in the Share Purchase Agreement. 

 

Purchase consideration   Amount  

Cash paid up to September 30, 2026

  $ 13,600  
Purchase consideration payable as of September 30, 2026     1,400  
Common stock     12,000  
Preferred stock (convertible into common stock)     18,000  
Earnout consideration     5,000  
Total   $ 50,000  

 

The Company is in the process of determining the fair values of the identifiable assets acquired and liabilities assumed as of the acquisition date in accordance with ASC 805, Business Combinations. As the initial accounting for the business combination is incomplete as of the date of these financial statements, the Company has not yet finalized the purchase price allocation. The provisional amounts recognized reflect management’s best estimates based on information available at this time.

 

The final purchase price allocation, including the determination of fair values of identifiable intangible assets, property and equipment, deferred tax assets and liabilities, and any resulting goodwill, will be completed as soon as practicable and within the measurement period of up to one year from the acquisition date as permitted under ASC 805-10-25-15. Any adjustments to the provisional amounts identified during the measurement period will be recognized in the reporting period in which the adjustment is determined, with a corresponding adjustment to goodwill.

 

33

 

 

Pending the purchase price allocation, the Company has provisionally recognized an amount of $53,547 as of January 1, 2026, as follows:

 

Current assets acquired:          
Cash and cash equivalents       $ 2  
Accounts receivable, net         4,998  
Other current assets         650  
Total current assets       $ 5,650  
Non-current assets acquired:            
Furniture and equipment, net       $ 1,494  
Operating lease right-of-use assets         1,419  
Other non-current assets         206  
Total assets acquired   (a)   $ 8,769  
             
Liabilities assumed:            
Accounts payable       $ 2,874  
Operating lease liabilities         749  
Short-term borrowing         5,659  
Other current liabilities         1,875  
Total current liabilities       $ 11,157  
Non-current liabilities assumed            
Long term debt         367  
Operating long-term lease liabilities         646  
Other non-current liabilities         146  
Total liabilities assumed   (b)     12,316  
Net liabilities assumed   (c = a – b)   $ (3,547 )
             
Preliminary intangible assets   (d)   $ 53,547  
Total purchase consideration allocated (pending purchase price allocation)   (c + d)   $ 50,000  

 

Successful Integration of Teyame into the Healthcare Triangle

 

A critical factor to the success of the acquisition will be Healthcare Triangle’s ability to effectively integrate Teyame’s operations, technology platforms, people, and the go-to-market strategy into HCTI’s broader healthcare operations. The integration process includes aligning product development roadmap, simplifying operational processes, consolidating administrative functions, and creating a combined portfolio of customer impacting solutions.

 

Healthcare Triangle expects the acquisition to enhance its capabilities in artificial intelligence-driven healthcare technologies, automation, data analytics, and intelligent workflow management. Successful integration will depend on maintaining operational continuity, retaining key personnel and customers, and minimizing disruptions during the transition period.

 

In addition, the integration of Teyame’s AI-driven capabilities with HCTI’s cloud infrastructure, data platforms, and healthcare technology services is expected to create cross-functional synergies that may improve scalability, customer engagement, and long-term recurring revenue opportunities.

 

Cross-selling and customer expansion opportunities

 

The acquisition enables Healthcare Triangle to cross-sell Teyame’s solutions into its existing customer base while simultaneously introducing HCTI’s broader portfolio of cloud, cybersecurity, managed services and data engineering to Teyame’s customers.

 

These combined customer relationships may increase enterprise engagements and enhance our data, analytics and automation offerings. Healthcare organizations increasingly prefer integrated technology partners capable of delivering end-to-end digital transformation solutions, and the acquisition may strengthen HCTI’s ability to provide such comprehensive offerings.

 

Future growth will depend on the Company’s ability to execute coordinated sales and marketing initiatives, demonstrate measurable value to customers, and maintain high customer retention and satisfaction levels.

 

34

 

 

Adoption of Artificial Intelligence (AI) and enhancement of our Healthcare Technology capabilities

 

The acquisition of Teyame is expected to accelerate the pace of innovation and strengthen HCTI’s strategic position within the rapidly growing healthcare artificial intelligence market. Through the acquisition, HCTI intends to expand its scalable AI-driven capabilities and enhance its portfolio of solutions focused on clinical workflow optimization, patient engagement, operational efficiency, predictive analytics, and intelligent automation.

 

As healthcare organizations increasingly adopt AI-enabled technologies to improve clinical outcomes, care delivery, streamline operations, and enhance decision-making, HCTI believes the combined technology solutions will support the expansion of differentiated service offerings across hospitals, health systems, and life sciences organizations. The acquisition is also expected to enhance HCTI’s ability to integrate advanced analytics, automation, and data-driven intelligence into its broader healthcare technology ecosystem.

 

The Company’s future success will depend on its ability to continuously enhance product functionality, maintain technological relevance in a rapidly evolving healthcare environment, and deliver measurable clinical, operational, and financial outcomes for customers. HCTI believes these capabilities will be important drivers of customer adoption, long-term retention, recurring revenue growth, and overall market expansion.

 

Adoption of our solutions by new and existing customers

 

We believe that our ability to increase our customer base will enable us to drive growth. Most of our customers initially deploy our solutions within a division or geography and may only initially deploy a limited set of our available solutions. Our future growth is dependent upon our existing customers’ continued success and renewals of our solutions agreements, deployment of our solutions to additional divisions or geographies, and the purchase of subscriptions to additional solutions. Our growth is also dependent on the adoption of our solutions by new customers. Our customers are large organizations who typically have long procurement cycles which may lead to declines in the pace of our new customer additions.

 

Subscription services adoption

 

The key factor to our success in generating substantial recurring subscription revenues in future will be our ability to successfully market and persuade new customers to adopt our Software as a Service (“SaaS”) offerings. We are in the early stages of marketing our SaaS offerings such as DataEz, CloudEz and Readabl.AI, and do not yet have enough information about our competition or customer acceptance to determine whether or not recurring subscription revenue from these offerings will have a material impact on our revenue growth.

 

Mix of solutions and software services revenues

 

Another factor to our success is the ability to sell our solutions to the existing software services customers. During the initial period of deployment by a customer, we generally provide a greater number of services including advisory, implementation and training. At the same time, many of our customers have historically purchased our solutions after the deployment. Hence, the proportion of total revenues for a customer associated with software services is relatively high during the initial deployment period. While our software services help our customers achieve measurable improvements and make them stickier, they have lower gross margins than solution-based revenue. Over time, we expect the revenues to shift towards recurring and subscription-based revenues.

 

35

 

 

Components of Results of Operations

 

Revenues

 

During the quarters ended September 30, 2026, and 2025, the Company generated revenues of approximately $9.12 million compared to revenue of $3.49 million respectively, which represents an increase of $5.63 million or 161% compared to the previous year comparative quarter.

 

We provide our services and manage our business under these operating segments:

 

  ● Software Services
     
  ● Managed Services and Support
     
  ● Customer Engagement Services
     
  ●

All others

 

Software Services

 

The Company earns revenue primarily through the sale of software services that is generated from providing strategic advisory, implementation, and development services. The Company enters into Statement of Work (SOW) which provides for service obligations that need to be fulfilled as agreed with the customer. The majority of our software services arrangements are billed on a time and materials basis, and revenues are recognized over time based on time incurred and contractually agreed upon rates. Certain software services revenues are billed on a fixed fee basis and revenues are typically recognized over time as the services are delivered based on time incurred and customer acceptance. We recognize revenue when we have the right to invoice the customer using the allowable practical expedient under ASC 606-10-55-18 since the right to invoice the customer corresponds with the performance obligations completed.

 

Managed Services and Support

 

Managed Services and Support include post implementation support and cloud hosting. Managed Services and Support are a distinct performance obligation. Revenue for Managed Services and Support is recognized ratably over the life of the contract.

 

Customer Engagement Services

 

The Customer Engagement Services segment, acquired through business combination (see note 6), provides customer search, marketing, telemarketing and customer-support services to financial institutions, insurance companies and intermediaries, and other customers. These services include the promotion and distribution of banking, credit and insurance products; outbound and inbound telemarketing; lead generation and customer-search campaigns; appointment setting; customer service and satisfaction surveys; and technology-enabled digital marketing and customer-interaction services supporting customers’ digital search and customer-care strategies.

 

The Company recognizes revenue from Customer Engagement Services in accordance with ASC 606, Revenue from Contracts with Customers. Revenue is recognized when or as the Company satisfies its performance obligations by transferring the promised services to the customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those services.

 

Under these arrangements, the Company generally performs the customer-engagement services using its own personnel, processes, systems and operational infrastructure and is primarily responsible for fulfilling the promised services in accordance with contractual requirements and applicable quality standards. The Company has determined that it controls the specified services before they are transferred to the customer and, accordingly, acts as the principal in these arrangements and recognizes revenue on a gross basis.

 

Consideration under Customer Engagement Services arrangements is generally based on either a fee for each completed and validated outcome or an agreed hourly rate for services provided.

 

For success-based arrangements, revenue is recognized at a point in time when the applicable contractual outcome has been completed and validated by the customer in accordance with contractual terms. To the extent such consideration is variable, revenue is recognized only to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur.

 

36

 

 

For hourly service arrangements, revenue is recognized over time as the services are performed because the customer simultaneously receives and consumes the benefits of the Company’s performance. Revenue is measured based on the contracted hourly rate and the actual hours of service provided during the applicable reporting period.

 

Revenue is presented net of estimated cancellations, penalties and other adjustments to the extent such amounts represent adjustments to the transaction price under the applicable customer contracts.

 

All others

 

This segment includes Platform Services revenue. A typical Platform Services contract would provide for some or all of the following types of services being provided to the customer: Data Analytics, Backup and Recovery, through our Platform with contract terms unique to each customer. The Company delivers Platform Services through its proprietary platform. Where third-party technology or infrastructure is included in the arrangement, the Company evaluates whether it is acting as principal or agent based on whether it controls the service before transfer to the customer.

 

The revenue from Platform services is a distinct performance obligation and recognized based on SSP. During the periods presented the Company generated revenue from Platform services on a fixed-price solutions delivery model. Revenues related to fixed-price contracts are recognized as the service is performed using the cost-to-cost method, under which the total value of revenues is recognized based on the percentage that each contract’s total labor cost to date bears to the total expected labor costs. The cost-to-cost method requires estimation of future costs, which is updated as the project progresses to reflect the latest available information; such estimates and changes in estimates involve the use of judgment. The cumulative impact of any revision in estimates is reflected in the financial reporting period in which the change in estimate becomes known and any anticipated losses on contracts are recognized in full in the period in which the loss becomes probable and estimable.

 

Our contractual terms and conditions for revenue mandate that our services are documented and subject to inspection, testing at the time of delivery to customer. In addition, the Company needs to integrate seamlessly into the customers’ systems. Also, the customer has a right to cancel all, or part of the services rendered if it is not in accordance with statement of work and within the stipulated time.

 

Cost of Revenue

 

Cost of revenue consists primarily of employee-related costs associated with the rendering of our services, including salaries, benefits and stock-based compensation expense, the cost of subcontractors, travel costs, cloud hosting charges and allocated overhead the cost of providing professional services is significantly higher as a percentage of the related revenues than for our subscription services due to the direct labor costs and costs of subcontractors. Our business and operational models are designed to be highly scalable and leverage variable costs to support revenue-generating activities. 

 

While we may grow our headcount overtime to capitalize on our market opportunities, we believe our increased investment in automation, electronic health record integration capabilities, and economies of scale in our operating model, will position us to grow our platform solutions revenue at a greater rate than our cost of revenue.

 

Gross Margin

 

The gross margin generated by the Company has increased to 23% in the quarter ended September 30, 2026, as compared to 18% in the quarter ended September 30, 2025, respectively.

 

The Customer Engagement Services segment generated $1.82 million in segment gross profit at a gross margin of approximately 28%, above the Company’s historical margin profile. The continued strength of this segment was the single largest driver of the Company’s overall gross margin expansion, to 23% in the quarter ended September 30, 2026, from 18% in the quarter ended September 30, 2025. 

 

Going forward, we expect the gross margin to continue to increase, as new contracts are being negotiated at higher margins and as a result, we expect future profit margins to increase materially over the next few quarters.

 

Operating Expenses

 

Research and Development

 

Research and development expense (majorly our investment in innovation) consists primarily of employee-related expenses, including salaries, benefits, incentives, employment taxes, severance, and equity compensation costs for our software developers, engineers, analysts, project managers, and other employees engaged in the development and enhancement of our cloud-based platform applications. Research and development expenses also include certain third-party consulting fees. Our research and development expense excludes any depreciation and amortization.

 

We expect to continue our focus on developing new product offerings and enhancing our existing product offerings. As a result, we expect our future research and development expense to increase in absolute dollars, although it may vary from period to period as a percentage of revenue.

 

37

 

 

Sales and Marketing

 

Sales and marketing expense consists primarily of employee-related expenses, including salaries, benefits, commissions, travel, discretionary incentive compensation, employment taxes, severance, and equity compensation costs for our employees engaged in sales, sales support, business development, and marketing. Sales and marketing expense also includes operating expenses for marketing programs, research, trade shows, and brand messages, and public relations costs.

 

We expect our future sales and marketing expenses to continue to increase in absolute dollar terms as we strategically invest to expand our business, although it may vary from period to period as a percentage of total revenues.

 

General and Administrative

 

Our general and administrative expenses consist primarily of employee-related expenses including salaries, benefits, discretionary incentive compensation, employment taxes, severance, and stock-based compensation expenses, for employees who are responsible for management information systems, administration, human resources, finance, legal, and executive management. The general and administrative expenses also include occupancy expenses (including rent, utilities, and facilities maintenance), professional fees, consulting fees, insurance, travel, contingent consideration, transaction costs, integration costs, and other expenses. Our general and administrative expenses exclude depreciation and amortization.

 

In the nearest future, we expect our general and administrative expenses to continue to increase to support business growth. Over the long term, we expect general and administrative expenses to decrease as a percentage of revenue.

 

Depreciation and Amortization Expenses

 

Our depreciation and amortization expense consists primarily of depreciation of fixed assets, amortization of customer relationship and capitalized software development costs, and amortization of intangible assets. We expect our depreciation and amortization expense to increase as we continue to invest and expand our business organically and through acquisitions. 

 

Other Income (Expense), Net

 

Other income (expense), net consists of finance cost and gains or losses on foreign currency.

 

Deferred Revenues

 

Advanced billings to clients in excess of revenue earned are recorded as deferred revenue until the revenue recognition criteria are met. 

 

Results of Operations

 

The following tables set forth selected unaudited condensed consolidated statements of operations and comprehensive loss data and such data as a percentage of total revenues for each of the periods indicated:

 

    Quarter ended
September 30,
 
    2026     % Sales     2025     % Sales  
             
Revenue   $ 9,116       100 %   $ 3,489       100 %
Less:                                
Cost of revenue (exclusive of depreciation /amortization)     7,035       77 %     2,871       82 %
Sales and marketing     1,538       17 %     1,022       29 %
General and administrative     2,213       24 %     2,085       60 %
Research and development     231       3 %     59       2 %
Bad debts expense / (reversal)     26       - %     (20 )     (1 )%
Depreciation and amortization     74       1 %     63       2 %
Other income     (190 )     (2 )%     (731 )     (21 )%
Changes in fair value     629       7 %     -       - %
Interest expense     80       1 %     32       1 %
Forex loss     26       - %     14       - %
Loss before income tax   $ (2,546 )     (28 )%   $ (1,906 )     (55 )%

 

38

 

 

Revenue from operations

 

    Quarter ended
September 30,
    Changes  
    2026     2025     Amount     %  
                                 
Revenue   $ 9,116     $ 3,489     $ 5,627       161 %

 

Revenue increased by $5.63 million, or 161%, to $9.12 million for the quarter ended September 30, 2026, as compared to $3.49 million for the quarter ended September 30, 2025. Revenue from Customer Engagement Services, and All others increased in the current quarter, while revenue from Software Services and Managed Services and Support decreased.

 

Our top 5 customers accounted for 58% of the revenue in quarter ended September 30, 2026, and 56% during quarter ended September 30, 2025, respectively.

 

The following table has the breakdown of our revenues for the quarter ended September 30, 2026, and 2025 for each of our top 5 customers.

 

Top Five Customers Revenue for quarter ended September 30, 2026, and 2025.

 

(In thousands, except percentages)

 

    Quarter ended
September 30, 2026
    Quarter ended
September 30, 2025
 
Customer   Amount     % of Revenue     Amount     % of Revenue  
Customer 1   $ 2,647       29 %   $ 689       20 %
Customer 2     745       8 %     583       17 %
Customer 3     688       8 %     296       8 %
Customer 4     663       7 %     235       7 %
Customer 5   $ 588       6 %   $ 133       4 %

 

(*) acquired as part of business combination during the period ended September 30, 2026.

 

The following table provides details of Customer 1 revenue by operating segments:

 

    Quarter ended
September 30,
    Changes  
    2026     2025     Amount     %  
       
Software services   $ -     $ -     $ -       - %
Customer engagement services     2,647       -       2,647       100 %
Managed services and support     -       689       (689 )     (100 )%
Total Revenue   $ 2,647     $ 689     $ 1,958       284 %

 

Total revenue from Customer 1 increased by $1.96 million, or 284%, to $2.65 million for the quarter ended September 30, 2026, as compared to $0.69 million for the quarter ended September 30, 2025. Customer 1 did not generate Software Services revenue in either the quarter ended September 30, 2026, or the quarter ended September 30, 2025. Customer engagement services revenue increased by $2.65 million, or 100%, to $2.65 million for the quarter ended September 30, 2026, as compared to nil for the quarter ended September 30, 2025. Managed Services and Support revenue decreased by $0.69 million, or 100%, to nil for the quarter ended September 30, 2026, as compared to $0.69 million for the quarter ended September 30, 2025.

 

Cost of Revenue (exclusive of depreciation/amortization)

 

    Quarter ended
September 30,
    Changes  
    2026     2025     Amount     %  
                                 
Cost of revenue (exclusive of depreciation/amortization)   $ 7,035     $ 2,871     $ 4,164       145 %

 

Cost of revenue, excluding depreciation and amortization, increased by $4.16 million, or 145%, to $7.04 million for the quarter ended September 30, 2026, as compared to $2.87 million for the quarter ended September 30, 2025.

 

39

 

 

Research and Development

 

    Quarter ended
September 30,
    Changes  
    2026     2025     Amount     %  
                                 
Research and development   $ 231     $ 59     $ 172       292 %

 

Research and Development expenses increased by $0.17 million, or 292%, to $0.23 million for the quarter ended September 30, 2026, as compared to $0.06 million for the quarter ended September 30, 2025.

  

Sales and Marketing

 

    Quarter ended
September 30,
    Changes  
    2026     2025     Amount     %  
                         
Sales and marketing   $ 1,538     $ 1,022     $ 516       50 %

 

Sales and Marketing expenses increased by $0.52 million, or 50%, to $1.54 million for the quarter ended September 30, 2026, as compared to $1.02 million for the quarter ended September 30, 2025.

 

Sales and Marketing expenses for the quarters ended September 30, 2026, and 2025, were $1,538 and $1,022, of which advertisement expenses were $891 and $649 respectively.

 

General and Administrative

 

    Quarter ended
September 30,
    Changes  
    2026     2025     Amount     %  
                                 
General and administrative   $ 2,213     $ 2,085     $ 128       6 %

 

General and Administrative expenses increased by $0.13 million, or 6%, to $2.21 million for the quarter ended September 30, 2026, as compared to $2.09 million for the quarter ended September 30, 2025.

 

Depreciation and Amortization

 

    Quarter ended
September 30,
    Changes  
    2026     2025     Amount     %  
                                 
Depreciation and amortization   $ 74     $ 63     $ 11       17 %

 

Depreciation and Amortization expenses increased by $0.01 million, or 17%, to $0.07 million for the quarter ended September 30, 2026, as compared to $0.06 million for the quarter ended September 30, 2025.

 

40

 

 

Interest Expense

 

    Quarter ended
September 30,
    Changes  
    2026     2025     Amount     %  
                                 
Interest expense   $ 80     $ 32     $ 48       150 %

 

Interest expenses increased by $0.05 million, or 150%, to $0.08 million for the quarter ended September 30, 2026, as compared to $0.03 million for the quarter ended September 30, 2025.

 

Other income

 

    Quarter ended
September 30,
    Changes  
    2026     2025     Amount     %  
                         
Other income   $ 190     $ 731     $ (541 )      (74 )%

 

Other income decreased by $0.54 million, or 74%, to $0.19 million for the quarter ended September 30, 2026, as compared to $0.73 million for the quarter ended September 30, 2025.

 

Changes in fair value

 

    Quarter ended              
    September 30,              
    (In thousands)     Changes  
    2026     2025     Amount     %  
Changes in fair value   $ 629     $ -     $ 629       100 %

 

Changes in fair value increased by $0.63 million, or 100%, to $0.63 million for the quarter ended September 30, 2026, as compared to nil for the quarter ended September 30, 2025.

 

Forex loss

 

    Quarter ended              
    September 30,              
    (In thousands)     Changes  
    2026     2025     Amount     %  
Forex loss   $ 26     $ 14     $ 12       86 %

 

Forex loss increased by $0.01 million, or 86%, to $0.03 million for the quarter ended September 30, 2026, as compared to $0.01 million for the quarter ended September 30, 2025.

 

Nine Months Ended September 30, 2026, Compared to Nine Months Ended September 30, 2025

 

Revenue increased by $17.41 million, or 162%, to $28.16 million for the nine months ended September 30, 2026, as compared to $10.75 million for the nine months ended September 30, 2025, primarily due to $19.71 million of revenue from the Customer Engagement Services segment acquired effective January 1, 2026. Revenue from Software Services decreased by $2.00 million, or 32%, to $4.30 million, and revenue from Managed Services and Support decreased by $0.30 million, or 7%, to $3.94 million, while revenue from All others remained unchanged at $0.21 million.

 

Cost of revenue, excluding depreciation and amortization, increased by $12.31 million, or 132%, to $21.62 million for the nine months ended September 30, 2026, as compared to $9.31 million for the nine months ended September 30, 2025, primarily due to $14.22 million of cost of revenue of the Customer Engagement Services segment. Gross margin increased to 23.2% for the nine months ended September 30, 2026, from 13.4% for the nine months ended September 30, 2025.

 

41

 

 

Sales and marketing expenses increased by $2.03 million, or 101%, to $4.04 million; general and administrative expenses increased by $5.79 million, or 130%, to $10.25 million; and research and development expenses increased by $0.11 million, or 43%, to $0.37 million, in each case for the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025, primarily reflecting the inclusion of the acquired Teyame and Datono operations and transaction, integration and professional costs. Depreciation and amortization increased by $1.34 million to $1.41 million, primarily due to amortization of intellectual property and depreciation of furniture and equipment.

 

Changes in fair value of $3.72 million for the nine months ended September 30, 2026 (nil for the nine months ended September 30, 2025) relate to the 2025 Convertible Notes and 2026 Convertible Notes, which are measured at fair value (see note 10). Interest expense decreased by $0.21 million, or 46%, to $0.25 million, and other income decreased by $0.22 million, or 26%, to $0.64 million. As a result, net loss increased to $13.15 million for the nine months ended September 30, 2026, from $4.97 million for the nine months ended September 30, 2025.

 

Revenue, Cost of Revenue and Operating Profit by Operating Segments

 

During the three months ended September 30, 2026, the Company refined and simplified the presentation of its segment disclosures in accordance with ASC 280, Segment Reporting, to better align with the financial information regularly provided to its Chief Operating Decision Makers (“CODMs”) for evaluating operating performance and allocating resources.

 

We manage and report our business under four operating segments which are Software Services, Managed Services and Support, Customer Engagement Services, and All others.

 

The revised presentation focuses on reportable segment revenues, the measure of segment profit or loss used by the CODMs and other disclosures required under ASC 280. Amounts previously presented under “Corporate and Others” have been reclassified, as applicable, to “All others” non-reportable business activities or unallocated corporate reconciling items, as corporate activities do not constitute a reportable operating segment.

 

Comparative segment information for the three and nine months ended September 30, 2025 has been reclassified to conform to the current-period presentation. These changes have no impact on the Company’s previously reported consolidated financial position, results of operations or cash flows.

 

    Quarter ended
September 30,
    Changes  
    2026     2025     Amount     %  
Software services   $ 1,202     $ 2,040     $ (838 )     (41 )%
Managed services and support     1,316       1,379       (63 )     (5 )%
Customer engagement services(*)     6,525       -       6,525       100 %
All others     73       70       3       4 %
Revenue   $ 9,116     $ 3,489     $ 5,627       161 %

 

42

 

 

Revenue from Software services decreased by $0.84 million, or 41% to $1.20 million for the quarter ended September 30, 2026, as compared to $2.04 million for the quarter ended September 30, 2025. Revenue from Managed services and support decreased by $0.06 million, or 5% to $1.32 million for the quarter ended September 30, 2026, as compared to $1.38 million for the quarter ended September 30, 2025. Revenue from Customer engagement services increased by 100% to $6.53 million for the quarter ended September 30, 2026, as compared to nil for the quarter ended September 30, 2025. Revenue from all others increased by 4% to $0.07 million for the quarter ended September 30, 2026, as compared to $0.07 million for the quarter ended September 30, 2025.

 

Factors affecting revenues of Software Services, and Managed Services and Support

 

Our strategy is to achieve meaningful long-term revenue growth through sales of Managed Services and Support to existing and new clients within our target market. In order to increase our cross-selling opportunity between our operating segments and realize long time revenue growth, our focus has shifted more towards Managed Services and Support which is of recurring nature when compared to Software Services segment which is of non-recurring nature. This also helps in retaining existing customers by leveraging our Managed Services and Support and Platform Services as a growth agent. This renewed focus on driving demand for subscription and platform-based model will help us in expanding our customer base and enhance customer retention which is a challenge for our existing Software Services segment. Software Services contracts are driven by Time and Material and on-site employees delivering services at customers location.

 

Cost of Revenue

 

    Quarter ended
September 30,
    Changes  
    2026     2025     Amount     %  
                         
Software services   $ 1,041     $ 1,738     $ (697 )     (40 )%
Managed services and support     1,009       1,092       (83 )     (8 )%
Customer engagement services     4,706       -       4,706       100 %
All others     279       41       238       580 %
Cost of revenue   $ 7,035     $ 2,871     $ 4,164       145 %

 

Cost of revenue for Software services decreased by $0.70 million, or 40%, to $1.04 million for the quarter ended September 30, 2026, as compared to $1.74 million for the quarter ended September 30, 2025. Cost of revenue for Managed Services and Support decreased by $0.08 million, or 8%, to $1.01 million for the quarter ended September 30, 2026, as compared to $1.09 million for the quarter ended September 30, 2025. Cost of revenue for Customer engagement services increased by $4.71 million, or 100% for the quarter ended September 30, 2026, as compared to nil for the quarter ended September 30, 2025. Cost of revenue for all others increased by $0.24 million, or 580%, to $0.28 million for the quarter ended September 30, 2026, as compared to $0.04 million for the quarter ended September 30, 2025.

 

Segment operating results by reportable segments were as follows:

 

Operating results by Operating Segment

 

Three months ended September 30, 2026
    Software
Services
    Managed
Services
    Customer
Engagement
Services*
    All
others
    Total
Reportable
 Segments
    Corporate
and other
items
    Consolidated
Total
 
Revenue   $ 1,202       1,316       6,525       73       9,116       -       9,116  
Cost of revenue     (1,041 )     (1,009 )     (4,706 )     (279 )     (7,035 )     -       (7,035 )
Sales and marketing     (117 )     (114 )     (444 )     -       (675 )     (863 )     (1,538 )
General and administrative     (186 )     (46 )     (1,259 )     -       (1,491 )     (722 )     (2,213 )
Others, net     (45 )     -       30       -       (15 )     (861 )     (876 )
Profit / (Loss) before income taxes   $ (187 )     147       146       (206 )     (100 )     (2,446 )     (2,546 )

 

(*) represents segment acquired as part of business combination. See note 6(B) for details.

 

43

 

 

Three months ended September 30, 20251
    Software
Services
    Managed
Services
    Others     Total
Reportable
 Segments
    Corporate
and other
items
    Consolidated
Total
 
Revenue   $ 2,040       1,379       70       3,489       -       3,489  
Cost of revenue     (1,738 )     (1,092 )     (41 )     (2,871 )     -       (2,871 )
Sales and marketing     (280 )     (173 )     -       (453 )     (569 )     (1,022 )
General and administrative     (652 )     (299 )     -       (951 )     (1,134 )     (2,085 )
Others, net     -       -       -       -       583       583  
Profit / (Loss) before income taxes   $ (630 )     (185 )     29       (786 )     (1,120 )     (1,906 )

 

(1) Comparatives have been rearranged for the purposes of comparison.

 

Due from related parties:

 

On January 1, 2025, the Company entered into a Master Service Agreement with SecureKloud Technologies Inc. (“SKI”) and SecureKloud Technologies Limited (“SKL”). The initial term of the agreement is twenty-four months, which is extendable based on mutual consent. As per the Master Services Agreement, SKI and SKL provide technical resources according to the statement of work from the Company. Pricing is determined using a cost-plus model, with a markup of 18% on cost, to ensure that the transactions comply with the arm’s length principle in accordance with the applicable transfer pricing regulations.

 

As of September 30, 2026, and December 31, 2025, the balances outstanding are $1,975, and $3,826 respectively. The balances are unsecured, non-interest bearing and are expected to be settled in the ordinary course of business, as outlined below:

 

-

$3,200 was advanced to SecureKloud Technologies Ltd. in connection with the design, develop and deliver an Integrated Health Advisory & Care Platform & Tools including certain artificial intelligence-enabled software tools and related intellectual property, intended to support the Company’s current and future product offerings, During the period ended September 30, 2026, progress billings amounting to $1,225 were moved to platform work-in-progress (See note 9), and accordingly, $1,975 remained as advance as of September 30, 2026.

 

44

 

 

On June 24, 2026, the Company entered into a Securities Exchange Agreement with SecureKloud pursuant to which certain preferred equity securities held by SecureKloud were exchanged for shares of the Company’s common stock on July 28, 2026, following receipt of stockholder approval. In connection with the July 28, 2026, exchange and extinguishment of the Series B Convertible Preferred Stock, the Company assessed the qualitative nature and integrated terms of its settlement with SecureKloud, a related party, and concluded that settlement of the $626 advance represented consideration transferred in the equity exchange rather than a separate settlement expense. Accordingly, the Company reversed the $626 provision during the period ended September 30, 2026, and included the advance settlement in the consideration accounted for directly within stockholders’ equity. The adjustment reduced third-quarter expense and the deemed contribution arising from the preferred-stock extinguishment by $626 each. The combined adjustment was noncash and had no effect on total stockholders’ equity at September 30, 2026. Management evaluated the quantitative and qualitative effects, including the nature of the transaction and its effects on earnings and earnings per share, and concluded that the matter was not material to the previously issued interim financial statements for the three and six months ended June 30, 2026, and that recognition of the adjustment in the third quarter did not materially affect the interim financial statements for the three and nine months ended September 30, 2026. See also note 13(B).

 

  C. Related party transactions:

 

Following are the transactions with related parties during the periods presented:

 

Related Parties   Nature of transactions   Quarter
ended
September 30,
2026
    Quarter
ended
September 30,
2025
 
SecureKloud Technologies Limited, India   Services received and paid for   $ 1,225     $ 470  
    Amounts advanced     -       525  
Healthcare Triangle (Pvt.) Limited, India   Services received and paid for     530       -  
    Amounts advanced     -       -  
SecureKloud Technologies, Inc.   Services received and paid for     -       -  
    Amounts advanced     -       -  
    Services rendered     -       -  
    Amounts collected by related party on behalf of the Company     -       27  
    Rent expenses paid     -       44  
Blockedge Technologies, Inc.   Services received and paid for     60       40  
    Amounts advanced     -       140  
    Revenue     -       9  
Key management personnel   Remuneration     309       133  
Board of Directors   Compensation     55       -  
    Amount advanced   $ 40       -  

 

During the period ended September 30, 2026, the Company issued 1,781,745 shares (89,087 shares, subsequent to one-for-twenty reverse stock-split effective October 26, 2026) of common stock to Blockedge Technologies Inc., a subsidiary of SecureKloud Technologies Limited, India, and 1,046,422 shares (52,321 shares, subsequent to one-for-twenty reverse stock-split effective October 26, 2026) to Robinson Vincent, on behalf of SecureKloud Technologies Limited, India, in connection with extinguishment of 1,600,000 Preferred B stock previously held by SecureKloud Technologies Limited, India.

 

45

 

 

Liquidity and Capital Resources

 

Liquidity

 

The current ratio measures a company’s ability to pay off its current liabilities (payable within one year) with its total current assets such as cash, accounts receivable, and inventories. The Company’s current ratio, as at September 30, 2026 is 0.62 compared to 1.03 as at December 31, 2025.

 

The Company’s debt equity ratio, as at September 30, 2026, is 0.25, compared to 1.08 as at December 31, 2025.

 

The Company does not have inventory and hence the quick ratio is the same as the current ratio.

 

Sources of Liquidity

 

    As of
September 30,
2026
    As of
September 30,
2025
 
                 
Cash and cash equivalents   $ 1,869     $ 1,629  

 

As of September 30, 2026, our principal sources of liquidity consisted of cash and cash equivalents of $1.87 million. We have financed our operations primarily through financing activities, including sales of our common stock and debt financing. We believe our existing cash and cash equivalents, together with funds available under our At-the-Market Sales Agreement and Equity Line of Credit, will be sufficient to meet our working capital requirements over the next 12 months. Our future capital requirements will depend on many factors including our growth rate, subscription renewal activity, the expansion of sales and marketing activities and the ongoing investments in platform development. 

 

We have incurred recurring losses from operations and negative operating cash flows, and as of September 30, 2026, our current liabilities of $14.38 million exceeded our current assets of $8.86 million. Our 2026 Convertible Notes, with a fair value of $3.60 million as of September 30, 2026, mature on December 12, 2026, and we are generally required to apply 25% of the net proceeds of specified financings toward their repayment. In addition, our ability to sell shares under the Equity Line of Credit and the At-the-Market Sales Agreement is subject to market conditions, trading volume, an effective registration statement and our continued listing on Nasdaq. On October 1, 2026, we received a Staff Delisting Determination from Nasdaq, and we are awaiting the decision of the Nasdaq Hearings Panel. If our common stock were delisted, or if we were otherwise unable to access these facilities on acceptable terms, our liquidity and our ability to fund operations and repay our obligations as they become due could be materially and adversely affected.

 

Cash Flows

 

The following table presents a summary of our consolidated cash flows provided by / (used in) operating, investing, and financing activities for the periods indicated:

 

    Nine months ended
September 30,
2026
    Nine months ended
September 30,
2025
 
       
Cash flows used in operating activities   $ (10,207 )   $ (10,156 )
Cash flows used in investing activities     (10,699 )     (1,289 )
Cash flows provided by financing activities     15,168       13,054  
Cumulative translation adjustment     (18 )     -  
Net (decrease) / increase in cash and cash equivalents   $ (5,756 )   $ 1,609  

 

Operating Activities

 

Net cash used in operating activities during the nine months ended September 30, 2026, was $(10.21) million compared to $(10.16) million for the nine months ended September 30, 2025.

 

46

 

 

Investing Activities

 

Net cash used in investing activities was $(10.70) million for the nine months ended September 30, 2026, compared to $(1.29) million for the nine months ended September 30, 2025.

 

Financing Activities

 

Net cash provided by financing activities was $15.17 million for the nine months ended September 30, 2026, compared to $13.05 million for the nine months ended September 30, 2025. 

 

Off-Balance Sheet Arrangements

 

We do not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes, as of September 30, 2026.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information required by this Item.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures and Changes in Internal Control over Financial Reporting

 

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) are designed to ensure that information required to be disclosed by us in reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Operating Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), as appropriate, to allow timely decisions regarding required disclosure. We, under the supervision of and with the participation of our management, including our Chief Operating Officer and Chief Financial Officer, have evaluated the effectiveness of our disclosure controls and procedures. Based on that evaluation, our Chief Operating Officer and Chief Financial Officer concluded that the design and operation of our disclosure controls and procedures were effective as of September 30, 2026. 

 

Changes in Internal Control over Financial Reporting 

 

There were no changes to our internal control over financial reporting during the quarter ended September 30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 

 

47

 

 

PART II

 

OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

From time to time, we may be involved in routine litigation that arises in the ordinary course of business.

 

The information concerning legal proceedings involving L1 Capital Global Opportunities Master Fund Ltd. disclosed in Note 15, Legal Matters, and Note 18, Subsequent Events, to the unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.

 

Item 1A. Risk Factors.

 

As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on April 15, 2026, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 16, 2026. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Except as previously reported in the Company’s Current Report on Form 8-K filed with the SEC on July 29, 2026 (relating to the issuance on July 28, 2026 of 9,718,373 shares (485,919 shares subsequent to the one-for-twenty reverse stock-split effective October 26, 2026) of common stock in connection with the Teyame acquisition and 2,828,167 shares (141,408 shares subsequent to such reverse stock-split) of common stock pursuant to the Securities Exchange Agreement with SecureKloud, each in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder), during the quarter ended September 30, 2026, the Company did not sell any equity securities that were not registered under the Securities Act.

 

Issuer Purchases of Equity Securities

 

On March 11, 2026, the Company announced a share repurchase program authorized by its Board of Directors on March 9, 2026, and effective immediately, permitting the repurchase of up to $2.0 million of its outstanding common stock. The repurchase program does not have an expiration date and may be suspended, modified or discontinued at any time at the Company’s discretion.

 

During the three months ended September 30, 2026, the Company repurchased an aggregate of 127,248 shares (6,362 shares subsequent to the one-for-twenty reverse stock-split effective October 26, 2026) of common stock in a single transaction under the publicly announced repurchase program.

 

Period   Total Number of Shares Purchased(1)     Average Price Paid per Share(1)     Shares Purchased Under Publicly Announced Program     Approximate Dollar Value Remaining Under Program  
September 1 - September 30, 2026     127,248     $ 0.768       127,248     $ 1.9 million  
Total     127,248     $ 0.768       127,248     $ 1.9 million  

 

The repurchase program permits purchases through open-market transactions, privately negotiated transactions or other permitted means, subject to applicable securities laws and market conditions.

 

(1) Total number of shares and the average price per share represent shares bought prior to the one-for-twenty reverse stock-split effective October 26, 2026. The value subsequent to the reverse stock-split are 6,362 shares and $15.36 per share respectively.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable

 

Item 5. Other Information

 

During the three months ended September 30, 2026, no director or officer adopted, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, in each case as defined in Item 408(a) of Regulation S-K.

 

48

 

 

Item 6. Exhibits

 

Exhibit No.   Description
2.1†          Separation and Distribution Agreement, dated as of September 2, 2026, by and between Healthcare Triangle, Inc. and Teyame AI Holdings, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 8, 2026).
10.1†   Transition Services Agreement, dated as of September 2, 2026, by and between Healthcare Triangle, Inc. and Teyame AI Holdings, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 8, 2026).
10.2   First Amendment to the Equity Purchase Agreement, dated September 22, 2026, by and between Healthcare Triangle, Inc. and Hudson Global Ventures, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 25, 2026).
21.1*   List of subsidiaries of the registrant
31.1*   Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*   Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**   Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**   Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*   Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*   Inline XBRL Taxonomy Extension Schema Document.
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

* Filed herewith.
   
** Furnished herewith (Exhibits 32.1 and 32.2 are not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934).
   
† Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.

 

49

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  HEALTHCARE TRIANGLE, INC.
   
Date: November 13, 2026 /s/ Sujatha Ramesh
  Sujatha Ramesh
  Board Director and Chief Operating Officer
  (Principal executive officer)
   
Date: November 13, 2026 /s/ David Ayanoglou 
  David Ayanoglou
  Chief Financial Officer
  (Principal financial officer)

 

50

 

Keep reading